CA2006596A1 - G-csf modifie chimiquement - Google Patents

G-csf modifie chimiquement

Info

Publication number: CA2006596A1
Authority: CA; Canada
Prior art keywords: csf; chemically; modified; gps; aminoacid
Prior art date: 1988-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA2006596A

Other languages

English (en)

Other versions

CA2006596C (fr

Inventor

Rika Ishikawa

Yuji Okada

Makoto Kakitani

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen K A Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-22

Filing date

1989-12-22

Publication date

1990-06-22

1989-12-22 Application filed by Individual filed Critical Individual

1989-12-22 Priority to CA002311684A priority Critical patent/CA2311684C/fr

1990-06-22 Publication of CA2006596A1 publication Critical patent/CA2006596A1/fr

2000-09-05 Application granted granted Critical

2000-09-05 Publication of CA2006596C publication Critical patent/CA2006596C/fr

2009-12-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
239000002202 Polyethylene glycol Substances 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
108091005573 modified proteins Proteins 0.000 abstract 1
102000035118 modified proteins Human genes 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/145—Colony stimulating factor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

CA002006596A 1988-12-22 1989-12-22 G-csf modifie chimiquement Expired - Lifetime CA2006596C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002311684A CA2311684C (fr)	1988-12-22	1989-12-22	G-csf modifie chimiquement

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP324747/88		1988-12-22
JP32474788		1988-12-22
JP199176/89		1989-07-31
JP19917689		1989-07-31

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002311684A Division CA2311684C (fr)	1988-12-22	1989-12-22	G-csf modifie chimiquement

Publications (2)

Publication Number	Publication Date
CA2006596A1 true CA2006596A1 (fr)	1990-06-22
CA2006596C CA2006596C (fr)	2000-09-05

Family

ID=26511383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002006596A Expired - Lifetime CA2006596C (fr)	1988-12-22	1989-12-22	G-csf modifie chimiquement

Country Status (7)

Country	Link
US (2)	US5824778A (fr)
EP (1)	EP0401384B1 (fr)
JP (1)	JP2989002B2 (fr)
AT (1)	ATE135370T1 (fr)
CA (1)	CA2006596C (fr)
DE (1)	DE68925966T2 (fr)
WO (1)	WO1990006952A1 (fr)

Families Citing this family (912)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5718893A (en) *	1984-04-15	1998-02-17	Foster; Preston F.	Use of G-CSF to reduce acute rejection
US20020177688A1 (en) *	1988-12-22	2002-11-28	Kirin-Amgen, Inc.,	Chemically-modified G-CSF
EP0401384B1 (fr) *	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
GB9107846D0 (en) *	1990-04-30	1991-05-29	Ici Plc	Polypeptides
US20060084797A1 (en) *	1990-06-11	2006-04-20	Gilead Sciences, Inc.	High affinity TGFbeta nucleic acid ligands and inhibitors
US6465188B1 (en) *	1990-06-11	2002-10-15	Gilead Sciences, Inc.	Nucleic acid ligand complexes
IE912365A1 (en) *	1990-07-23	1992-01-29	Zeneca Ltd	Continuous release pharmaceutical compositions
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US5336782A (en) *	1991-04-24	1994-08-09	Kuraray Co., Ltd.	Long chain carboxylic acid imide ester
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) *	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
DK0726778T3 (da) *	1994-02-08	2001-09-24	Amgen Inc	Oral administration af kemisk modificerede proteiner
ES2312166T3 (es)	1994-02-23	2009-02-16	Kyowa Hakko Kogyo Co., Ltd	Acelerador del crecimiento plaquetario.
US5795569A (en) *	1994-03-31	1998-08-18	Amgen Inc.	Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CN1229385C (zh) *	1994-03-31	2005-11-30	安姆根有限公司	刺激巨核细胞生长和分化的组合物及方法
US5536495A (en) *	1994-04-15	1996-07-16	Foster; Preston F.	Use of G-CSF to reduce acute rejection
US6124448A (en) *	1994-08-17	2000-09-26	The Rockfeller University	Nucleic acid primers and probes for the mammalian OB gene
US6471956B1 (en)	1994-08-17	2002-10-29	The Rockefeller University	Ob polypeptides, modified forms and compositions thereto
US6001968A (en)	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
US6429290B1 (en)	1994-08-17	2002-08-06	The Rockefeller University	OB polypeptides, modified forms and derivatives
US6124439A (en) *	1994-08-17	2000-09-26	The Rockefeller University	OB polypeptide antibodies and method of making
US6350730B1 (en)	1994-08-17	2002-02-26	The Rockefeller University	OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) *	1994-08-17	2000-04-11	The Rockefeller University	OB polypeptides as modulators of body weight
US20030053982A1 (en) *	1994-09-26	2003-03-20	Kinstler Olaf B.	N-terminally chemically modified protein compositions and methods
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7820798B2 (en)	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US5770577A (en) *	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
JP3708151B2 (ja) *	1994-12-15	2005-10-19	協和醗酵工業株式会社	Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US8071737B2 (en) *	1995-05-04	2011-12-06	Glead Sciences, Inc.	Nucleic acid ligand complexes
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
AU6028396A (en)	1995-06-07	1996-12-30	Amgen, Inc.	Ob protein compositions and method
US6184200B1 (en)	1995-09-28	2001-02-06	Amgen Inc.	Truncated glial cell line-derived neurotrophic factor
US5731284A (en) *	1995-09-28	1998-03-24	Amgen Inc.	Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US20030040467A1 (en)	1998-06-15	2003-02-27	Mary Ann Pelleymounter	Ig/ob fusions and uses thereof.
US6936439B2 (en)	1995-11-22	2005-08-30	Amgen Inc.	OB fusion protein compositions and methods
WO1997019693A1 (fr) *	1995-11-29	1997-06-05	Amgen Inc.	Procede de traitement des neuropathies sensorielles utilisant un produit proteique du facteur neurotrophique derive d'une lignee de cellules gliales
US5641750A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US7632922B1 (en)	1995-12-22	2009-12-15	Amgen, Inc.	Osteoprotegerin
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
US5837681A (en) *	1996-02-23	1998-11-17	Amgen Inc.	Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) *	1996-02-23	1999-07-27	Amgen Inc.	Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6713061B1 (en)	1996-03-12	2004-03-30	Human Genome Sciences, Inc.	Death domain containing receptors
US7357927B2 (en)	1996-03-12	2008-04-15	Human Genome Sciences, Inc.	Death domain containing receptors
WO1997033904A1 (fr)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Recepteurs contenant un domaine de mort cellulaire
US5741778A (en) *	1996-03-19	1998-04-21	Amgen Inc.	Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US7964190B2 (en)	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US6455277B1 (en)	1996-04-22	2002-09-24	Amgen Inc.	Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US7138251B1 (en)	1996-04-22	2006-11-21	Amgen Inc.	Polynucleotides encoding a neurotrophic factor receptor
US5766877A (en)	1996-05-10	1998-06-16	Amgen Inc.	Genes encoding art, an agouti-related transcript
US5919656A (en) *	1996-11-15	1999-07-06	Amgen Canada Inc.	Genes encoding telomerase protein 1
US7390891B1 (en)	1996-11-15	2008-06-24	Amgen Inc.	Polynucleotides encoding a telomerase component TP2
JP4771563B2 (ja)	1996-12-06	2011-09-14	アムジエン・インコーポレーテツド	Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6455040B1 (en)	1997-01-14	2002-09-24	Human Genome Sciences, Inc.	Tumor necrosis factor receptor 5
CA2277757C (fr)	1997-01-15	2008-09-16	Phoenix Pharmacologics, Inc.	Facteur de necrose des tumeurs modifie
US6433147B1 (en)	1997-01-28	2002-08-13	Human Genome Sciences, Inc.	Death domain containing receptor-4
US6342363B1 (en)	1997-01-28	2002-01-29	Human Genome Sciences, Inc.	Death domain containing receptor 4 nucleic acids and methods
US7452538B2 (en)	1997-01-28	2008-11-18	Human Genome Sciences, Inc.	Death domain containing receptor 4 antibodies and methods
US8329179B2 (en)	1997-01-28	2012-12-11	Human Genome Sciences, Inc.	Death domain containing receptor 4 antibodies and methods
US6872568B1 (en)	1997-03-17	2005-03-29	Human Genome Sciences, Inc.	Death domain containing receptor 5 antibodies
US20080076706A1 (en)	1997-07-14	2008-03-27	Bolder Biotechnology, Inc.	Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) *	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
ATE375363T1 (de) *	1997-07-14	2007-10-15	Bolder Biotechnology Inc	Derivate des wachstumshormons und verwandte proteine
US6043221A (en) *	1997-07-30	2000-03-28	Amgen Inc.	Method for preventing and treating hearing loss using a neuturin protein product
AU3072799A (en)	1998-03-19	1999-10-11	Human Genome Sciences, Inc.	Cytokine receptor common gamma chain like
US6858706B2 (en)	1998-04-07	2005-02-22	St. Jude Children's Research Hospital	Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US6492138B1 (en)	1998-05-21	2002-12-10	Amgen Canada Inc.	Polynucleotides encoding a novel SHC-binding protein
US5973119A (en) *	1998-06-05	1999-10-26	Amgen Inc.	Cyclin E genes and proteins
US5962636A (en) *	1998-08-12	1999-10-05	Amgen Canada Inc.	Peptides capable of modulating inflammatory heart disease
US6344541B1 (en)	1998-09-25	2002-02-05	Amgen Inc.	DKR polypeptides
DK1656952T3 (da)	1998-10-16	2014-01-20	Biogen Idec Inc	Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
DK1121382T3 (da)	1998-10-16	2006-11-13	Biogen Idec Inc	Interferon-beta-fusionsproteiner og deres anvendelser
PT1783222E (pt)	1998-10-23	2012-07-26	Kirin Amgen Inc	Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6773911B1 (en)	1998-11-23	2004-08-10	Amgen Canada Inc.	Apoptosis-inducing factor
US8288126B2 (en)	1999-01-14	2012-10-16	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
JP2002540065A (ja) *	1999-01-29	2002-11-26	アムジェンインコーポレーテッド	Ｇｃｓｆコンジュゲート
US6303749B1 (en)	1999-01-29	2001-10-16	Amgen Inc.	Agouti and agouti-related peptide analogs
SI1157037T1 (en) *	1999-01-29	2003-12-31	F. Hoffmann-La Roche Ag	Gcsf conjugates
US7708993B2 (en)	1999-02-03	2010-05-04	Amgen Inc.	Polypeptides involved in immune response
US7435796B1 (en)	1999-02-03	2008-10-14	Amgen Inc.	Antibodies which bind B7RP1
DK1149114T3 (da)	1999-02-03	2014-06-23	Amgen Inc	Polypeptider, der er involveret ved et immunrespons
US8624010B1 (en)	1999-02-03	2014-01-07	Steven K. Yoshinaga	Nucleic acids encoding B7RP1
EP2357192A1 (fr)	1999-02-26	2011-08-17	Human Genome Sciences, Inc.	Endokine alpha humain et methodes d'utilisation
US7459540B1 (en)	1999-09-07	2008-12-02	Amgen Inc.	Fibroblast growth factor-like polypeptides
US7408047B1 (en)	1999-09-07	2008-08-05	Amgen Inc.	Fibroblast growth factor-like polypeptides
US6900043B1 (en)	1999-09-21	2005-05-31	Amgen Inc.	Phosphatases which activate map kinase pathways
US6831158B2 (en) *	2000-01-10	2004-12-14	Maxygen Holdings Ltd.	G-CSF conjugates
SK11672002A3 (sk) *	2000-01-10	2002-12-03	Maxygen Holdings Ltd.	Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
US6646110B2 (en) *	2000-01-10	2003-11-11	Maxygen Holdings Ltd.	G-CSF polypeptides and conjugates
US6555660B2 (en) *	2000-01-10	2003-04-29	Maxygen Holdings Ltd.	G-CSF conjugates
DE60138364D1 (de)	2000-02-11	2009-05-28	Bayer Healthcare Llc	Gerinnungsfaktor vii oder viia konjugate
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
US7514239B2 (en)	2000-03-28	2009-04-07	Amgen Inc.	Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2206720A1 (fr)	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
CA2413160A1 (fr)	2000-06-15	2001-12-20	Human Genome Sciences, Inc.	Facteur de necrose tumorale humain delta et epsilon
ES2317917T3 (es)	2000-06-28	2009-05-01	Amgen Inc.	Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
MXPA03000311A (es) *	2000-07-12	2004-12-13	Gryphon Therapeutics Inc	Produccion y uso de moduladores de receptor de quimiocina.
US6716811B1 (en)	2000-07-20	2004-04-06	Affymax, Inc.	Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
PT1320542E (pt)	2000-08-08	2007-08-06	St Jude Childrens Res Hospital	Ácidos nucleicos de estreptococo de grupo b, polipéptidos, composições terapêuticas e vacinas correspondentes
CA2418006A1 (fr)	2000-08-18	2002-02-28	Dyax Corp.	Polypeptides de liaison pour proteine stimulatrice des lymphocytes b (blys)
US8435939B2 (en)	2000-09-05	2013-05-07	Biokine Therapeutics Ltd.	Polypeptide anti-HIV agent containing the same
EE200300089A (et) *	2000-09-08	2005-02-15	Gryphon Therapeutics, Inc.	Sünteetilised erütropoeesi stimuleerivad valgud, nende valmistamismeetodid ning kasutamine
JP4799803B2 (ja) *	2000-09-08	2011-10-26	マサチューセッツインスティテュートオブテクノロジー	Ｇ−ｃｓｆアナログ組成物および方法
US7118737B2 (en) *	2000-09-08	2006-10-10	Amylin Pharmaceuticals, Inc.	Polymer-modified synthetic proteins
US20020142964A1 (en) *	2000-11-02	2002-10-03	Nissen Torben Lauesgaard	Single-chain polypeptides
CN1321134C (zh) *	2000-11-23	2007-06-13	赵剑	一种生物活性蛋白质的非均一制品及其制备方法
AU2002220720B2 (en)	2000-11-28	2006-09-14	Mondobiotech Ag	Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
AU1796902A (en)	2000-11-28	2002-06-11	Amgen Inc	Novel polypeptides involved in immune response
US8273713B2 (en) *	2000-12-14	2012-09-25	Amylin Pharmaceuticals, Llc	Methods of treating obesity using PYY[3-36]
US6979556B2 (en)	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
EP1683865A3 (fr)	2001-02-02	2006-10-25	Eli Lilly & Company	Protéines de mammifères en particulier CD200
JP2005503116A (ja)	2001-02-09	2005-02-03	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
EP2080771A3 (fr)	2001-02-27	2010-01-06	Maxygen Aps	Nouvelles molécules de type interféron beta
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2444632A1 (fr)	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Facteur de croissance 2, endothelial, vasculaire
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
MXPA03010747A (es)	2001-05-25	2004-03-02	Human Genome Sciences Inc	Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
PL371781A1 (en)	2001-07-11	2005-06-27	Maxygen Holdings, Ltd.	G-csf conjugates
US20040077835A1 (en) *	2001-07-12	2004-04-22	Robin Offord	Chemokine receptor modulators, production and use
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
KR100968664B1 (ko)	2001-08-27	2010-07-06	제넨테크, 인크.	항체 발현 및 조립을 위한 시스템
KR100989647B1 (ko)	2001-09-24	2010-10-26	오레곤 헬스 앤드 사이언스 유니버시티	식습관의 변화
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7795210B2 (en)	2001-10-10	2010-09-14	Novo Nordisk A/S	Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en)	2001-10-10	2011-08-30	Novo Nordisk A/S	Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en)	2001-11-28	2007-01-02	Neose Technologies, Inc.	Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) *	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP1461300B1 (fr)	2001-11-30	2011-07-27	Biogen Idec MA Inc.	Anticorps contre des proteines chimiotactiques de monocytes
AU2002347182A1 (en)	2001-12-18	2003-06-30	Mondobiotech Licensing Out Ag	Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
EP2261250B1 (fr)	2001-12-21	2015-07-01	Human Genome Sciences, Inc.	Protéines de fusion d'albumine et GCSF
EP1474163A2 (fr)	2002-01-10	2004-11-10	Imperial College Innovations Limited	Modification des habitudes alimentaires
US8058233B2 (en)	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US7662924B2 (en)	2002-02-22	2010-02-16	The Board Of Trustees Of The University Of Illinois	Beta chain-associated regulator of apoptosis
DE10209822A1 (de) *	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
US7557195B2 (en)	2002-03-20	2009-07-07	Biopolymed, Inc.	Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
CA2488358A1 (fr)	2002-06-10	2003-12-18	Mondobiotech Laboratories Anstalt	Utilisation de composes presentant l'activite biologique du peptide intestinal vasoactif pour traiter une sarcoidose
ATE494002T1 (de) *	2002-06-14	2011-01-15	Amylin Pharmaceuticals Inc	Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
MXPA04012496A (es)	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
RU2362807C2 (ru)	2002-06-21	2009-07-27	Ново Нордиск Хелт Кэр Аг	Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция
US20040219142A1 (en)	2002-07-19	2004-11-04	Abbott Laboratories S.A.	Treatment of skin and nail disorders using TNFalpha inhibitors
WO2004020462A1 (fr)	2002-08-27	2004-03-11	Fujii, Nobutaka	Antagoniste de cxcr4 et son utilisation
BR0314106A (pt) *	2002-09-11	2005-07-19	Fresenius Kabi De Gmbh	Polipeptìdeos hasilados, especialmente eritropoietina hasilada
TWI281864B (en) *	2002-11-20	2007-06-01	Pharmacia Corp	N-terminally monopegylated human growth hormone conjugates and process for their preparation
EP2112229A3 (fr)	2002-11-25	2009-12-02	Sequenom, Inc.	Procédés d'identification du risque du cancer du sein et traitements associés
DK1585546T3 (da)	2002-12-30	2008-12-08	Biogen Idec Inc	KIM- 1- Antagonister og Brug til at Modulere Immunsystem
US8034900B2 (en) *	2002-12-30	2011-10-11	Amylin Pharmaceuticals, Inc.	Water-soluble thioester and selenoester compounds and methods for making and using the same
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
EP1585815A4 (fr)	2003-01-21	2006-02-22	Bristol Myers Squibb Co	Polynucleotide codant une nouvelle co-enzyme d'acyle a, monoacylglycerol acyltransferase-2 (mgat2), et utilisations de ceux-ci
CA2513213C (fr)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
NZ581460A (en)	2003-01-31	2010-02-26	Biogen Idec Inc	Polymer conjugates of mutated neublastin
KR20060003862A (ko)	2003-03-14	2006-01-11	네오스 테크놀로지스, 인크.	수용성분기폴리머 및 그 접합체
WO2004085648A2 (fr)	2003-03-19	2004-10-07	Biogen Idec Ma Inc.	Proteine de liaison de recepteur de nogo
KR20040083268A (ko) *	2003-03-21	2004-10-01	한미약품 주식회사	안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
US20050281778A1 (en) *	2003-03-28	2005-12-22	Myung-Ok Park	Human growth hormone conjugated with biocompatible polymer
US20060134736A1 (en) *	2003-03-28	2006-06-22	Jacobs John W	Human growth hormone conjugated with biocompatible polymer
AU2004224466B2 (en) *	2003-03-28	2008-01-03	Biopolymed Inc.	Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
US8791070B2 (en)	2003-04-09	2014-07-29	Novo Nordisk A/S	Glycopegylated factor IX
EP2055189A1 (fr)	2003-04-09	2009-05-06	Neose Technologies, Inc.	Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
EP1633440B1 (fr) *	2003-04-15	2008-05-14	Opperbas Holding B.V.	Composition pharmaceutique contenant des proteines et/ou des polypeptides et des particules colloidales
CA2864810A1 (fr)	2003-04-18	2004-11-04	Biogen Idec Ma, Inc.	Neublastine a conjugaison polymere glycosylee
AU2004240553A1 (en)	2003-05-09	2004-12-02	Neose Technologies, Inc.	Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2004100997A2 (fr)	2003-05-12	2004-11-25	Affymax, Inc.	Nouveau fragment espaceur de composes peptidiques modifies par du poly(ethylene glycol)
JP2007530440A (ja)	2003-05-12	2007-11-01	アフィーマックス・インコーポレイテッド	新規ポリ（エチレングリコール）修飾化合物およびその用途
WO2005012484A2 (fr)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Conjugues anticorps-toxines
US20080274948A1 (en) *	2003-08-08	2008-11-06	Fresenius Kabi Deutschland Gmbh	Conjugates of Hydroxyalkyl Starch and G-Csf
WO2005014655A2 (fr) *	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugues d'amidon d'hydroxyalkyle et de proteine
DE602004029173D1 (de)	2003-10-10	2010-10-28	Novo Nordisk As	Il-21-derivate
EP2633866A3 (fr)	2003-10-17	2013-12-18	Novo Nordisk A/S	Thérapie combinée
US7220407B2 (en)	2003-10-27	2007-05-22	Amgen Inc.	G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
US8633157B2 (en)	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
US7956032B2 (en)	2003-12-03	2011-06-07	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) *	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
WO2005053730A1 (fr) *	2003-12-05	2005-06-16	Kirin Beer Kabushiki Kaisha	Agent therapeutique contre l'insuffisance cardiaque terminale
NZ547157A (en)	2003-12-10	2009-07-31	Medarex Inc	Interferon Alpha Antibodies and their uses
RS53984B1 (sr)	2003-12-10	2015-10-30	E. R. Squibb & Sons L.L.C.	Ip-10 antitela i njihove upotrebe
US7338933B2 (en)	2004-01-08	2008-03-04	Neose Technologies, Inc.	O-linked glycosylation of peptides
EP2327724A3 (fr)	2004-02-02	2011-07-27	Ambrx, Inc.	Polypeptides d'hormone de croissance humaine et leur utilisations
ES2567634T3 (es)	2004-02-09	2016-04-25	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina
WO2005077094A2 (fr)	2004-02-11	2005-08-25	Amylin Pharmaceuticals, Inc.	Motifs de la famille de polypeptides pancreatiques et polypeptides les renfermant
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
EP1718665B1 (fr)	2004-02-11	2013-04-10	Amylin Pharmaceuticals, LLC	Polypeptides hybrides presentant des proprietes pouvant etre choisies
TWI417303B (zh)	2004-03-11	2013-12-01	Fresenius Kabi De Gmbh	經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
ES2390885T3 (es) *	2004-03-11	2012-11-19	Fresenius Kabi Deutschland Gmbh	Conjugados de hidroxialquilalmidón y una proteína
US7807176B2 (en)	2004-03-19	2010-10-05	Genomidea, Inc.	Polypeptide promoting vascular endothelial cell growth
AU2005227322A1 (en)	2004-03-23	2005-10-06	Biogen Idec Ma Inc.	Receptor coupling agents and therapeutic uses thereof
TWI439284B (zh)	2004-04-09	2014-06-01	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
KR101699142B1 (ko)	2004-06-18	2017-01-23	암브룩스, 인코포레이티드	신규 항원-결합 폴리펩티드 및 이의 용도
HUE035082T2 (en)	2004-06-21	2018-05-02	Squibb & Sons Llc	Interferon alpha receptor 1 antibodies and their use
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
PT1776136E (pt)	2004-06-24	2012-12-05	Biogen Idec Inc	Tratamento de estados que envolvem desmielinização
WO2006010057A2 (fr)	2004-07-08	2006-01-26	Amgen Inc.	Peptides therapeutiques
WO2006010143A2 (fr)	2004-07-13	2006-01-26	Neose Technologies, Inc.	Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
JP2008507280A (ja)	2004-07-21	2008-03-13	アンブレツクス・インコーポレイテツド	非天然コードアミノ酸を用いた生合成ポリペプチド
EP2479277B1 (fr)	2004-07-22	2015-09-02	Five Prime Therapeutics, Inc.	L'utilisation de MGD-CSF dans le traitement de maladie d'Alzheimer
CA2576193A1 (fr)	2004-08-03	2006-02-16	Biogen Idec Ma Inc.	Influence du taj sur les fonctions neuronales
WO2006031811A2 (fr)	2004-09-10	2006-03-23	Neose Technologies, Inc.	Interferon alpha glycopegyle
US20080176790A1 (en)	2004-10-29	2008-07-24	Defrees Shawn	Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US20060153799A1 (en) *	2004-11-05	2006-07-13	Northwestern University	Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
MX2007006830A (es)	2004-12-13	2008-02-07	Amylin Pharmaceuticals Inc	Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
JP2008525473A (ja)	2004-12-22	2008-07-17	アンブレツクス・インコーポレイテツド	修飾されたヒト成長ホルモン
GB2438760A (en)	2004-12-22	2007-12-05	Ambrx Inc	Methods for expression and purification of recombinant human growth hormone
CN102732588B (zh) *	2004-12-22	2015-01-07	Ambrx公司	氨酰基-tRNA合成酶的组合物及其用途
US7816320B2 (en)	2004-12-22	2010-10-19	Ambrx, Inc.	Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US9029331B2 (en)	2005-01-10	2015-05-12	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
WO2006081190A2 (fr)	2005-01-25	2006-08-03	Five Prime Therapeutics, Inc.	Compositions et methodes de traitement de troubles cardiaques
US7402730B1 (en)	2005-02-03	2008-07-22	Lexicon Pharmaceuticals, Inc.	Knockout animals manifesting hyperlipidemia
BRPI0606992A2 (pt)	2005-02-11	2009-07-28	Amylin Pharmaceuticals Inc	análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) *	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
US7629315B2 (en)	2005-03-09	2009-12-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Compositions for blocking the inhibitory effect of human CRP on human leptin
AU2006222187A1 (en) *	2005-03-11	2006-09-14	Fresenius Kabi Deutschland Gmbh	Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
EP2258382A3 (fr)	2005-03-31	2014-05-14	Amylin Pharmaceuticals, LLC	Amyline et agonistes d'amyline pour traiter les maladies et les troubles psychiatriques
CA2602654A1 (fr)	2005-04-05	2006-10-12	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Procede permettant de proteger des sites fonctionnels ou des epitopes sur des proteines
US20070154992A1 (en)	2005-04-08	2007-07-05	Neose Technologies, Inc.	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9119901B2 (en)	2005-04-28	2015-09-01	Warsaw Orthopedic, Inc.	Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en)	2005-04-28	2013-04-09	Warsaw Orthopedic, Inc.	Coatings on medical implants to guide soft tissue healing
RU2494107C2 (ru)	2005-05-09	2013-09-27	Оно Фармасьютикал Ко., Лтд.	Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN102961746B (zh)	2005-05-16	2016-06-15	艾伯维生物技术有限公司	TNFα抑制剂治疗腐蚀性多关节炎的用途
EP1888098A2 (fr)	2005-05-25	2008-02-20	Neose Technologies, Inc.	Formulations d'erythropoietine glycopegylees
EP1891231A4 (fr) *	2005-05-25	2011-06-22	Novo Nordisk As	Facteur ix glycopegyle
US20070015701A1 (en) *	2005-06-01	2007-01-18	Samuel Zalipsky	Macromolecular conjugates of bone morphogenetic protein-7
EP1888119B1 (fr) *	2005-06-01	2011-03-09	Maxygen, Inc.	Polypeptides g-csf pegyles et procedes de production correspondants
WO2006133089A2 (fr) *	2005-06-03	2006-12-14	Ambrx, Inc.	Molecules d'interferons humains ameliorees et utilisations de celles-ci
KR100694994B1 (ko)	2005-06-13	2007-03-14	씨제이 주식회사	사람 과립구 콜로니 형성인자 동종체
EP1893632B1 (fr)	2005-06-17	2015-08-12	Novo Nordisk Health Care AG	Reduction et derivation séléctives de proteines facteur vii comprenant au moins une cysteine non native
CN104356236B (zh)	2005-07-01	2020-07-03	E.R.施贵宝&圣斯有限责任公司	抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7482124B2 (en)	2005-07-08	2009-01-27	Bristol-Myers Squibb Company	Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
SI1904104T1 (sl)	2005-07-08	2013-12-31	Biogen Idec Ma Inc.	Protitelesa SP35 in njihova uporaba
EP1910542B1 (fr)	2005-07-22	2009-12-02	Five Prime Therapeutics, Inc.	Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr
EP2330124B1 (fr)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Polypeptides hybrides ayant des propriétés sélectionnables
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
MX2008002149A (es)	2005-08-18	2008-04-22	Ambrx Inc	Composiciones de arnt y sus usos.
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
ES2736184T3 (es)	2005-08-19	2019-12-26	Amylin Pharmaceuticals Llc	Exendina para el tratamiento de la diabetes y la reducción del peso corporal
EP1762250A1 (fr) *	2005-09-12	2007-03-14	Fresenius Kabi Deutschland GmbH	Conjugués d' amidon hydroxyalkyle et une substance active obtenue par ligation chimique via thiazolidine
EA015860B1 (ru)	2005-10-13	2011-12-30	Хьюман Дженом Сайенсиз, Инк.	Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
RU2421464C2 (ru)	2005-10-21	2011-06-20	Новартис Аг	Человеческие антитела к il-13 и их терапевтическое применение
DK2500360T3 (en)	2005-10-31	2015-10-26	Oncomed Pharm Inc	Compositions and methods for the diagnosis and treatment of cancer
NZ567286A (en)	2005-11-01	2012-03-30	Abbott Biotechnolgy Ltd	Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2007056191A2 (fr)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Purification de sucre de nucleotide en utilisant des membranes
KR20080080109A (ko)	2005-11-04	2008-09-02	바이오겐 아이덱 엠에이 인코포레이티드	도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
CN104710503B (zh) *	2005-11-08	2023-04-25	Ambrx 公司	用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
EP1951890A4 (fr) *	2005-11-16	2009-06-24	Ambrx Inc	Procedes et compositions comprenant des acides amines non naturels
CA2631181A1 (fr)	2005-12-02	2007-06-07	Biogen Idec Ma Inc.	Traitement d'etats lies a la demyelination
US8383118B2 (en)	2005-12-08	2013-02-26	Medarex, Inc.	Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
DK1968635T3 (en) *	2005-12-14	2014-12-15	Ambrx Inc	Compositions and Methods of, and uses of non-natural amino acids and polypeptides
CA2913655A1 (fr)	2006-01-27	2007-08-09	Biogen Ma Inc.	Antagonistes des recepteurs nogo
TW200745163A (en)	2006-02-17	2007-12-16	Syntonix Pharmaceuticals Inc	Peptides that block the binding of IgG to FcRn
EP2004683B1 (fr)	2006-03-24	2016-05-11	Biogen Hemophilia Inc.	Protéine pc5 utilisée comme enzyme de traitement du propeptide du facteur ix
KR20140071452A (ko)	2006-04-05	2014-06-11	애브비 바이오테크놀로지 리미티드	항체 정제
EP2007426A4 (fr)	2006-04-10	2010-06-16	Abbott Biotech Ltd	Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
EP2703010A3 (fr)	2006-04-10	2014-08-06	AbbVie Biotechnology Ltd	Utilisations et compositions pour le traitement de l'arthrite rhumatoïde
CA2564435A1 (fr)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methodes de controle et de traitement des troubles intestinaux
ES2495741T3 (es)	2006-04-20	2014-09-17	Amgen, Inc	Compuestos de GLP-1
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
US8299024B2 (en) *	2006-05-12	2012-10-30	Amylin Pharmaceuticals, Llc	Methods to restore glycemic control
MX2008014744A (es)	2006-05-19	2009-02-10	Glycofi Inc	Composiciones de eritrocpoyetina.
KR20090013816A (ko)	2006-05-24	2009-02-05	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP2236623A1 (fr)	2006-06-05	2010-10-06	Cancer Care Ontario	Evaluation du risque dans le cancer colorectal
EP1872790A1 (fr)	2006-06-26	2008-01-02	DeveloGen Aktiengesellschaft	Nouvelle formulation pour augmenter la biodisponibilité de neurturine
KR101396797B1 (ko)	2006-06-30	2014-05-26	애브비 바이오테크놀로지 리미티드	자동 주사 장치
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
ES2516694T3 (es)	2006-07-21	2014-10-31	Ratiopharm Gmbh	Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
EP2074209A2 (fr)	2006-07-28	2009-07-01	Children's Memorial Hospital	Procédés d'inhibition de l'agressivité des cellules tumorales à l'aide du microenvironnement des cellules souches embryonnaires humaines
JP5256199B2 (ja)	2006-08-07	2013-08-07	テヴァバイオファーマシューティカルズユーエスエー，インコーポレーティッド	アルブミン−インスリン融合タンパク質
ITMI20061624A1 (it)	2006-08-11	2008-02-12	Bioker Srl	Mono-coniugati sito-specifici di g-csf
TW200817437A (en)	2006-08-11	2008-04-16	Medarex Inc	Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
MX2009002418A (es)	2006-09-05	2009-04-23	Medarex Inc	Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
EP2064333B1 (fr) *	2006-09-08	2014-02-26	Ambrx, Inc.	Transcription d'arnt suppresseur dans des cellules de vertébrés
MX2009002460A (es) *	2006-09-08	2009-03-20	Ambrx Inc	Arnt supresor hibrido para celulas de vertebrados.
CN106008699A (zh) *	2006-09-08	2016-10-12	Ambrx公司	经修饰的人类血浆多肽或Fc骨架和其用途
US7985783B2 (en)	2006-09-21	2011-07-26	The Regents Of The University Of California	Aldehyde tags, uses thereof in site-specific protein modification
KR101722261B1 (ko)	2006-10-02	2017-04-03	메다렉스, 엘.엘.시.	Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
US8969532B2 (en)	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008060814A2 (fr)	2006-10-19	2008-05-22	Merck & Co., Inc.	ANTICORPS DIRIGÉS CONTRE IL-13Rα1 ET LEURS UTILISATIONS
US8618248B2 (en)	2006-10-31	2013-12-31	President And Fellows Of Harvard College	Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
KR20090088891A (ko)	2006-11-15	2009-08-20	메다렉스, 인코포레이티드	비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
KR101552735B1 (ko)	2006-12-01	2015-09-14	메다렉스, 엘.엘.시.	씨디22에 결합하는 인간 항체 및 이의 용도
PL2121751T3 (pl)	2006-12-08	2017-07-31	Lexicon Pharmaceuticals, Inc.	Przeciwciała monoklonalne przeciwko ANGPTL3
CL2007003622A1 (es)	2006-12-13	2009-08-07	Medarex Inc	Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
KR20090088946A (ko)	2006-12-14	2009-08-20	메다렉스, 인코포레이티드	씨디70에 결합하는 인간 항체 및 이의 용도
CA2673719C (fr)	2006-12-21	2018-07-24	Biokine Therapeutics Ltd.	Analogues peptidiques de t-140 presentant une activite superagoniste par rapport a cxcr4 destines a une extraction de moelle osseuse
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
EP2114427B1 (fr)	2007-01-30	2014-06-25	New York University	Peptides destinés à être utilisés dans un traitement d'états associés à de l'oxyde nitrique
US8106154B2 (en)	2007-01-31	2012-01-31	Affymax, Inc.	Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
SG178744A1 (en)	2007-02-02	2012-03-29	Biogen Idec Inc	Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US20110189663A1 (en)	2007-03-05	2011-08-04	Cancer Care Ontario	Assessment of risk for colorectal cancer
CA2682147C (fr)	2007-03-30	2017-08-08	Ambrx, Inc.	Polypeptides fgf-21 modifies, et leurs utilisations
KR20100016160A (ko)	2007-04-03	2010-02-12	바이오제너릭스 에이지	글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
MX2009011870A (es)	2007-05-02	2009-11-12	Ambrx Inc	Polipeptidos de interferon beta modificados y usos de los mismos.
EP2679996A1 (fr)	2007-05-31	2014-01-01	AbbVie Inc.	Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
EP2171451A4 (fr)	2007-06-11	2011-12-07	Abbott Biotech Ltd	Procédés de traitement de l'arthrite idiopathique juvénile
WO2008154639A2 (fr)	2007-06-12	2008-12-18	Neose Technologies, Inc.	Procédé amélioré pour la production de sucres de nucléotide
EP2578677A1 (fr)	2007-08-09	2013-04-10	Genzyme Corporation	Procédé de traitement d'une maladie auto-immune avec des cellules souches mésenchymateuses
MX2010001363A (es)	2007-08-09	2010-03-09	Syntonix Pharmaceuticals Inc	Peptidos inmunomoduladores.
DE202008017456U1 (de)	2007-08-27	2009-08-27	Biogenerix Ag	Flüssig-Formulierung von G-CSF-Konjugaten
US8207112B2 (en)	2007-08-29	2012-06-26	Biogenerix Ag	Liquid formulation of G-CSF conjugate
WO2009032845A2 (fr)	2007-09-04	2009-03-12	Compugen, Ltd.	Polypeptides et polynucléotides, et leurs utilisations comme cibles de médicaments pour la production de médicaments et de substances biologiques
US8758761B2 (en)	2007-09-30	2014-06-24	University Of Florida Research Foundation, Inc.	Combination therapies for treating type 1 diabetes
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
KR20100091170A (ko)	2007-11-02	2010-08-18	노파르티스 아게	저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
MX2010005317A (es) *	2007-11-20	2010-06-02	Ambrx Inc	Polipeptidos de insulina modificados y sus usos.
KR101615935B1 (ko)	2007-12-14	2016-04-28	노보 노르디스크 에이/에스	인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
EP2070950A1 (fr) *	2007-12-14	2009-06-17	Fresenius Kabi Deutschland GmbH	Dérivés hydroxyalkylés de l'amidon et leur procédé de préparation
EP2070951A1 (fr) *	2007-12-14	2009-06-17	Fresenius Kabi Deutschland GmbH	Procédé de production d'un dérivé hydroxyalkyle de l'amidon avec deux liens
NZ587440A (en)	2008-02-05	2013-01-25	Pfizer	Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
NZ586947A (en)	2008-02-08	2012-11-30	Ambrx Inc	Modified leptin polypeptides and their uses
HRP20160855T1 (hr)	2008-02-08	2016-09-23	Medimmune, Llc	Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
WO2009103199A1 (fr)	2008-02-18	2009-08-27	江苏恒瑞医药股份有限公司	Conjugué de g-csf modifié par un polymère hydrosoluble
KR101582841B1 (ko)	2008-02-27	2016-01-11	노보 노르디스크 에이/에스	콘쥬게이트된 인자 ｖｉｉｉ 분자
CA2717320A1 (fr)	2008-03-11	2009-09-17	Sequenom, Inc.	Tests adn pour determiner le sexe d'un bebe avant sa naissance
JP5670875B2 (ja)	2008-03-17	2015-02-18	ウニベルジテーツクリニクムミュンスター	カーゴ分子の送達ビヒクルおよび炎症反応を免疫調節するための生物学的治療剤としてのＹｏｐＭ
EP2260102A1 (fr)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Traitement du cancer par régulation à la baisse de frizzled-4 et/ou frizzled-1
PL2274331T3 (pl)	2008-05-02	2014-04-30	Novartis Ag	Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
EP2303313B1 (fr)	2008-05-21	2015-10-28	Amylin Pharmaceuticals, LLC	Exendines pour diminuer le cholestérol et les triglycérides
EP2296690B1 (fr)	2008-06-04	2016-11-30	Amgen, Inc	Mutants fgf21 et leurs utilisations
DK2982695T3 (da)	2008-07-09	2019-05-13	Biogen Ma Inc	Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
PT2318029T (pt)	2008-07-23	2018-01-10	Ambrx Inc	Polipéptidos de g-csf bovino modificados e suas utilizações
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8476013B2 (en)	2008-09-16	2013-07-02	Sequenom, Inc.	Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en)	2008-09-16	2015-02-24	Sequenom, Inc.	Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
MX2011003272A (es)	2008-09-26	2011-04-28	Ambrx Inc	Polipeptidos de eritropoyetina animal modificados y sus usos.
PE20110480A1 (es)	2008-09-26	2011-07-01	Ambrx Inc	Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
JP5878757B2 (ja)	2008-10-10	2016-03-08	アムジエン・インコーポレーテツド	Ｆｇｆ２１変異体およびその使用
ITRM20080551A1 (it) *	2008-10-15	2010-04-16	Univ Catania	Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici.
AU2009347206C1 (en)	2008-10-20	2016-12-08	Abbvie Inc.	Isolation and purification of antibodies using Protein A affinity chromatography
RU2472806C1 (ru) *	2008-10-20	2013-01-20	Юсв Лимитед	Усовершенствованный способ пегилирования белков
EP2356251A1 (fr)	2008-11-07	2011-08-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Teneurine et cancer
JP5746040B2 (ja)	2008-12-03	2015-07-08	ゲンマブエー／エス	定常領域の中に改変を有する抗体変種
WO2010067308A2 (fr)	2008-12-08	2010-06-17	Compugen Ltd.	Polypeptides et polynucléotides, et utilisations de ceux-ci en tant que médicament cible pour produire des médicaments et des agents biologiques
US20100260752A1 (en)	2009-01-23	2010-10-14	Biosynexus Incorporated	Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US9155780B2 (en)	2009-02-11	2015-10-13	Yeda Research And Development Co. Ltd.	Short beta-defensin-derived peptides
US8420084B2 (en)	2009-03-05	2013-04-16	Medarex, Inc.	Fully human antibodies specific to CADM1
RU2406528C2 (ru) *	2009-03-05	2010-12-20	Общество С Ограниченной Ответственностью "Саентифик Фьючер Менеджмент"	Средство для регенеративной медицины
US20110311521A1 (en)	2009-03-06	2011-12-22	Pico Caroni	Novel therapy for anxiety
CA2757114C (fr)	2009-03-30	2019-05-21	Universite De Lausanne	Preparation d'anticorps monoclonaux anti-edar agonistes isoles
US8580732B2 (en)	2009-04-07	2013-11-12	Duke University	Peptide therapy for hyperglycemia
EP2241323A1 (fr)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascine-W et cancers du cerveau
AU2010237046B2 (en)	2009-04-17	2015-06-04	New York University	Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
DK2421898T3 (en)	2009-04-20	2016-05-30	Oxford Biotherapeutics Ltd	Cadherin-17 SPECIFIC ANTIBODIES
EP2424894A1 (fr)	2009-04-27	2012-03-07	Novartis AG	Composition et procédés d'utilisation d'anticorps thérapeutiques spécifiques du sous-motif bêta-1 des récepteurs d'il-12
JP5766179B2 (ja)	2009-04-27	2015-08-19	ノバルティスアーゲー	筋肉増殖を増加させるための組成物および方法
KR101721906B1 (ko)	2009-04-29	2017-03-31	애브비 바이오테크놀로지 리미티드	자동 주입 장치
HRP20240135T1 (hr)	2009-05-05	2024-04-12	Amgen Inc.	Fgf21 mutanti i njihove upotrebe
EP2427207B1 (fr)	2009-05-05	2017-08-16	Amgen, Inc	Mutants de fgf21 et leurs utilisations
US9427456B2 (en)	2009-06-14	2016-08-30	Biokine Therapeutics Ltd.	Peptide therapy for increasing platelet levels
US8324160B2 (en)	2009-06-17	2012-12-04	Amgen Inc.	Chimeric polypeptides and uses thereof
JP6059985B2 (ja)	2009-06-18	2017-01-11	ファイザー・インク	抗ｎｏｔｃｈ−１抗体
CN102762593B (zh)	2009-07-31	2015-05-20	梅达雷克斯有限责任公司	抗btla的完全人抗体
WO2011021146A1 (fr)	2009-08-20	2011-02-24	Pfizer Inc.	Anticorps contre l'ostéopontine
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
WO2011029823A1 (fr)	2009-09-09	2011-03-17	Novartis Ag	Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés
WO2011036118A1 (fr)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Traitement du cancer par modulation de mex-3
EP2470569A1 (fr)	2009-10-13	2012-07-04	Oxford Biotherapeutics Ltd.	Anticorps anti-epha10
WO2011045352A2 (fr)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Tyrosine kinase de la rate et cancers du cerveau
ES2813398T3 (es)	2009-10-20	2021-03-23	Abbvie Inc	Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
US20110098862A1 (en)	2009-10-27	2011-04-28	ExxonMobil Research Engineering Company Law Department	Multi-stage processes and control thereof
WO2011051327A2 (fr)	2009-10-30	2011-05-05	Novartis Ag	Petites protéines à chaîne unique de type anticorps
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
WO2011051466A1 (fr)	2009-11-02	2011-05-05	Novartis Ag	Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
PH12012500843A1 (en)	2009-11-04	2019-07-10	Merck Sharp & Dohme	Engineered anti-tslp antibody
AU2010321587A1 (en)	2009-11-23	2012-06-07	Amylin Pharmaceuticals, Inc.	Polypeptide Conjugate
WO2011067711A2 (fr)	2009-12-01	2011-06-09	Compugen Ltd	Nouvelle variante d'épissage d'héparanase
UA109888C2 (uk)	2009-12-07	2015-10-26		ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
NZ627052A (en)	2009-12-15	2015-12-24	Abbvie Biotechnology Ltd	Improved firing button for automatic injection device
US20110150891A1 (en)	2009-12-16	2011-06-23	Philip Bosch	Methods of Treating Interstitial Cystitis
NZ600361A (en)	2009-12-21	2014-06-27	Ambrx Inc	Modified bovine somatotropin polypeptides and their uses
JP2013515081A (ja)	2009-12-21	2013-05-02	アンブルックス，インコーポレイテッド	修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EP3088532B1 (fr)	2009-12-22	2019-10-30	Sequenom, Inc.	Procédés et kits pour identifier une aneuploïdie
AU2010334974A1 (en)	2009-12-22	2012-07-12	Novartis Ag	Tetravalent CD47-antibody constant region fusion protein for use in therapy
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
WO2011092233A1 (fr)	2010-01-29	2011-08-04	Novartis Ag	Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
JP2013518590A (ja)	2010-02-02	2013-05-23	アボツト・バイオテクノロジー・リミテツド	ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
JP2013519869A (ja)	2010-02-10	2013-05-30	ノバルティスアーゲー	筋肉成長のための方法および化合物
US8859736B2 (en)	2010-02-19	2014-10-14	The Board Of Regents Of The University Of Oklahoma	Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
WO2011109556A2 (fr)	2010-03-04	2011-09-09	Pfenex Inc.	Procédé pour la production de la protéine interféron recombinante soluble sans dénaturation
WO2011107586A1 (fr)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, ténascine-c et cancers du cerveau
CA2791841C (fr)	2010-03-05	2023-01-03	Rigshospitalet	Molecules chimeriques inhibitrices d'activation du complement
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
BR112012024565B1 (pt)	2010-03-26	2022-02-08	Trustees Of Dartmouth College	Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
NZ603033A (en)	2010-04-01	2014-06-27	Pfenex Inc	Methods for g-csf production in a pseudomonas host cell
CA2796055A1 (fr)	2010-04-15	2011-10-20	Amgen Inc.	Proteines de liaison au recepteur de fgf humain et a ?-klotho
GB201105584D0 (en)	2011-04-01	2011-05-18	Imp Innovations Ltd	Cancer methods
WO2011131611A1 (fr)	2010-04-19	2011-10-27	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Modulation de xrn1
US9018348B2 (en)	2010-04-27	2015-04-28	Agency For Science, Technology And Research	eIF4E binding peptides
KR20130066631A (ko)	2010-05-06	2013-06-20	노파르티스 아게	치료적 저밀도 지단백질-관련 단백질 ６（ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
EP4234698A3 (fr)	2010-05-06	2023-11-08	Novartis AG	Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
EP2569331A1 (fr)	2010-05-10	2013-03-20	Perseid Therapeutics LLC	Polypeptides inhibiteurs de vla4
US20130137628A1 (en)	2010-05-11	2013-05-30	Esperion Therapeutics, Inc.	Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP3705133B1 (fr)	2010-05-14	2024-06-26	Baxalta Incorporated	Chimères d'ospa et leur utilisation dans des vaccins
WO2011146727A1 (fr)	2010-05-19	2011-11-24	Philip Bosch	Méthodes de traitement de la cystite interstitielle
WO2011145085A2 (fr)	2010-05-21	2011-11-24	Procognia (Israel) Ltd	Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer
HRP20181598T1 (hr)	2010-06-03	2018-11-30	Abbvie Biotechnology Ltd	Uporaba i pripravci za liječenje hidradenitis suppurativa (hs)
WO2011154485A1 (fr)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Traitement du cancer par modulation de la kinase 3 stérile de mammifère de type 20
US8431532B2 (en)	2010-06-28	2013-04-30	Five Prime Therepeutics, Inc.	FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
EP2591101B1 (fr)	2010-07-09	2018-11-07	Bioverativ Therapeutics Inc.	Systèmes pour le traitement du facteur viii et procédés associés
RU2446173C1 (ru) *	2010-08-13	2012-03-27	Зао "Биокад"	Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
MA34521B1 (fr)	2010-08-17	2013-09-02	Ambrx Inc	Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en)	2010-08-17	2017-02-14	Ambrx, Inc.	Therapeutic uses of modified relaxin polypeptides
NZ607337A (en)	2010-08-20	2015-06-26	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
US20130171159A1 (en)	2010-09-10	2013-07-04	Brian Arthur Hemmings	Phosphorylated twist1 and metastasis
EP2616100B1 (fr)	2010-09-17	2016-08-31	Compugen Ltd.	Compositions et procédés de traitement d'un myélome multiple résistant aux médicaments
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
ES2630031T3 (es)	2010-09-28	2017-08-17	Aegerion Pharmaceuticals, Inc.	Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
EP2625203A1 (fr)	2010-10-05	2013-08-14	Novartis AG	Anticorps anti-il12rbêta1 et leur utilisation dans le traitement des troubles auto-immuns et inflammatoires
US20140093506A1 (en)	2010-11-15	2014-04-03	Marc Buehler	Anti-fungal-agents
JP5945277B2 (ja)	2010-11-15	2016-07-05	ファイブプライムセラピューティックスインコーポレイテッド	Ｆｇｆｒ１細胞外ドメイン併用療法
US9023791B2 (en)	2010-11-19	2015-05-05	Novartis Ag	Fibroblast growth factor 21 mutations
JP6033229B2 (ja)	2010-11-24	2016-11-30	レクシコンファーマシューティカルズインコーポレイテッド	Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体
JP6190723B2 (ja)	2010-12-01	2017-08-30	アルダーバイオホールディングスエルエルシー	抗ｎｇｆ組成物およびその使用
US9458240B2 (en)	2010-12-10	2016-10-04	Novartis Pharma Ag	Anti-BAFFR antibody formulations
SG191039A1 (en)	2010-12-15	2013-08-30	Wyeth Llc	Anti-notch1 antibodies
AU2012205384B2 (en)	2011-01-14	2015-09-10	Five Prime Therapeutics, Inc.	IL-27 antagonists for treating inflammatory diseases
MX360402B (es)	2011-01-24	2018-10-31	Abbvie Biotechnology Ltd	Dispositivos de inyeccion automaticos que tienen superficies de agarre sobremoldeadas.
BR112013026199A2 (pt)	2011-04-15	2017-11-07	Compugen Ltd	polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
WO2012149339A2 (fr)	2011-04-29	2012-11-01	Sequenom, Inc.	Quantification d'une minorité d'espèces d'acide nucléique
DK2683817T3 (da)	2011-05-10	2017-11-06	Danisco Us Inc	Termostabile carbonanhydraser og fremgangsmåder til anvendelse deraf
NO2707391T3 (fr)	2011-05-13	2018-04-07
TWI685505B (zh)	2011-05-20	2020-02-21	美商艾爾德生物控股有限責任公司	抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en)	2011-05-20	2017-06-15	H. Lundbeck A/S	Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
NZ717704A (en)	2011-05-20	2022-08-26	H Lundbeck As	Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
WO2012168259A1 (fr)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protéine tyrosine phosphatase de type non-récepteur 11 (ptpn11), et cancer du sein triple négatif
WO2012172495A1 (fr)	2011-06-14	2012-12-20	Novartis Ag	Compositions et procédés de ciblage du tem8 par des anticorps
MX2013014789A (es)	2011-06-16	2014-01-20	Novartis Ag	Proteinas solubles para utilizarse como productos terapeuticos.
CN103747803B (zh)	2011-06-22	2016-10-12	国家医疗保健研究所	抗axl抗体及其用途
AU2012273954A1 (en)	2011-06-22	2014-01-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-Axl antibodies and uses thereof
UA114478C2 (uk)	2011-06-28	2017-06-26	Берлін-Хемі Аг	Антитіло, яке специфічно зв'язується з bst1
WO2013001517A1 (fr)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
EP2726502A1 (fr)	2011-07-01	2014-05-07	Bayer Intellectual Property GmbH	Polypeptides de fusion de relaxine et leurs utilisations
HUE040276T2 (hu)	2011-07-01	2019-02-28	Novartis Ag	Eljárás metabolikus rendellenességek kezelésére
ES2582869T3 (es)	2011-07-05	2016-09-15	Bioasis Technologies Inc	Conjugados de P97-anticuerpo
CN103796670A (zh)	2011-07-08	2014-05-14	比奥根艾迪克依蒙菲利亚公司	因子viii嵌合和杂合多肽及其使用方法
ES2732475T3 (es)	2011-07-08	2019-11-22	Aegerion Pharmaceuticals Inc	Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
ES3005912T3 (en)	2011-07-22	2025-03-17	Csl Behring Gmbh	Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
MX2014002260A (es)	2011-08-31	2014-08-18	Amgen Inc	Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
TW201315742A (zh)	2011-09-26	2013-04-16	Novartis Ag	治療代謝病症之雙功能蛋白質
ES2925654T3 (es)	2011-09-30	2022-10-19	Dana Farber Cancer Inst Inc	Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
CN104039830A (zh)	2011-11-04	2014-09-10	诺华股份有限公司	低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
EP2776838A1 (fr)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Diagnostic précoce de maladies neurodégénératives
US20140314787A1 (en)	2011-11-08	2014-10-23	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Treatment for neurodegenerative diseases
CN114748605A (zh)	2011-11-29	2022-07-15	普罗克拉拉生物科学股份有限公司	噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CA2857597A1 (fr)	2011-11-30	2013-06-06	AbbVie Deutschland GmbH & Co. KG	Procedes et compositions pour determiner la reactivite a des traitements avec un inhibiteur de tnf-alpha
AU2012349735B2 (en)	2011-12-05	2016-05-19	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140103135A (ko)	2011-12-05	2014-08-25	노파르티스 아게	Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
PE20150159A1 (es)	2011-12-21	2015-02-08	Novartis Ag	Composiciones y metodos para anticuerpos que actuan sobre el factor p
WO2013102825A1 (fr)	2012-01-02	2013-07-11	Novartis Ag	Cdcp1 et cancer du sein
EP2623110A1 (fr)	2012-01-31	2013-08-07	CSL Behring GmbH	Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
KR20140126357A (ko)	2012-02-01	2014-10-30	컴퓨젠 엘티디.	C1orf32 항체 및 이의 암 치료를 위한 용도
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (fr)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Proteines de facteur viii de recombinaison
HK1206055A1 (en)	2012-03-02	2015-12-31	Sequenom, Inc.	Methods and processes for non-invasive assessment of genetic variations
HUP1200171A1 (hu)	2012-03-19	2013-09-30	Richter Gedeon Nyrt	Módszerek polipeptidek elõállítására
WO2013144240A1 (fr)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition de l'interleukine 8 et/ou de ses récepteurs cxcrl dans le traitement du cancer du sein surexprimant her2/her3
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9439942B2 (en)	2012-04-24	2016-09-13	Biokine Therapeutics Ltd.	Peptides and use thereof in the treatment of large cell lung cancer
WO2013162748A1 (fr)	2012-04-27	2013-10-31	The Trustees Of The University Of Pennsylvania	Variants d'anticorps anti-marqueur 1 endothélial de tumeur (tem1) et leurs utilisations
US20140004131A1 (en)	2012-05-04	2014-01-02	Novartis Ag	Antibody formulation
CN104470541A (zh)	2012-05-14	2015-03-25	比奥根艾迪克Ma公司	用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
TW201348246A (zh)	2012-05-21	2013-12-01	Abbvie Inc	利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US10504613B2 (en)	2012-12-20	2019-12-10	Sequenom, Inc.	Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en)	2012-05-21	2018-03-20	Sequenom, Inc.	Methods and compositions for analyzing nucleic acid
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
PL2859017T3 (pl)	2012-06-08	2019-07-31	Sutro Biopharma, Inc.	Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
US9216219B2 (en)	2012-06-12	2015-12-22	Novartis Ag	Anti-BAFFR antibody formulation
DK3421486T5 (da)	2012-06-22	2024-09-16	The Trustees Of Darthmouth College	Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
WO2014004639A1 (fr)	2012-06-26	2014-01-03	Sutro Biopharma, Inc.	Protéines de fc modifiées, comprenant des résidus d'acides aminés non naturels spécifiques de site, leurs conjugués, leur préparation et leurs procédés d'utilisation
WO2014001482A1 (fr)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Traitement de maladies par modulation d'un isoforme spécifique de mkl-1
AR091649A1 (es)	2012-07-02	2015-02-18	Bristol Myers Squibb Co	Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014006114A1 (fr)	2012-07-05	2014-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Nouveau traitement pour maladies neurodégénératives
EP3404105A1 (fr)	2012-07-06	2018-11-21	Bioverativ Therapeutics Inc.	Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
US20140093873A1 (en)	2012-07-13	2014-04-03	Sequenom, Inc.	Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
JP2015524802A (ja)	2012-07-27	2015-08-27	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	キメラｏｓｐａ分子を含む組成物およびその使用方法
ES2647082T3 (es)	2012-07-31	2017-12-19	Bioasis Technologies Inc	Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
HRP20220455T1 (hr)	2012-08-31	2022-05-27	Sutro Biopharma, Inc.	Modificirane aminokiseline koje sadrže azid grupu
JP6368308B2 (ja)	2012-09-07	2018-08-01	トラスティーズ・オブ・ダートマス・カレッジ	癌の診断および治療のためのｖｉｓｔａ調節剤
US9376489B2 (en)	2012-09-07	2016-06-28	Novartis Ag	IL-18 binding molecules
CN104870008B (zh)	2012-10-02	2019-10-01	普罗克拉拉生物科学股份有限公司	噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
CA2888806A1 (fr)	2012-10-18	2014-04-24	Biogen Idec Ma Inc.	Procedes d'utilisation d'une dose fixe d'un facteur de coagulation
EP3446700A1 (fr)	2012-10-30	2019-02-27	Bioverativ Therapeutics Inc.	Procédé d'utilisation de polypeptide du facteur viii
AU2013341711A1 (en)	2012-11-12	2015-05-21	Redwood Bioscience, Inc.	Compounds and methods for producing a conjugate
EP2733153A1 (fr)	2012-11-15	2014-05-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés pour la préparation d'immunoconjugués et leurs utilisations
US9310374B2 (en)	2012-11-16	2016-04-12	Redwood Bioscience, Inc.	Hydrazinyl-indole compounds and methods for producing a conjugate
CN104870423A (zh)	2012-11-16	2015-08-26	加利福尼亚大学董事会	用于蛋白质化学修饰的pictet-spengler连接反应
WO2014084859A1 (fr)	2012-11-30	2014-06-05	Novartis Ag	Molécules et procédés pour la modulation d'activités de tmem16a
HUE053669T2 (hu)	2012-12-05	2021-07-28	Novartis Ag	Készítmények és eljárások EPO-t célzó antitestekre
US9383357B2 (en)	2012-12-07	2016-07-05	Northwestern University	Biomarker for replicative senescence
TWI617574B (zh)	2012-12-11	2018-03-11	梅迪繆思有限公司	用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
LT2953969T (lt)	2013-02-08	2019-12-10	Novartis Ag	Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
CA2901225C (fr)	2013-03-08	2023-09-19	Csl Behring Gmbh	Traitement et prevention d'une lesion d'ischemie reperfusion distante
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
HK1216655A1 (zh)	2013-03-13	2016-11-25	Sequenom, Inc.	用於dna甲基化分析的引物
JP6586412B2 (ja)	2013-03-13	2019-10-02	バイオアシステクノロジーズインコーポレイテッド	ｐ９７のフラグメントおよびその使用
WO2014142882A1 (fr)	2013-03-14	2014-09-18	Abbvie Inc.	Purification de protéine utilisant une chromatographie de déplacement
EP2970479B1 (fr)	2013-03-14	2019-04-24	Novartis AG	Anticorps dirigés contre notch 3
AU2014230472A1 (en)	2013-03-14	2015-10-01	Medimmune Limited	Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
KR20150130462A (ko)	2013-03-15	2015-11-23	다나-파버 캔서 인스티튜트 인크.	치료 펩티드
DK2968477T3 (da)	2013-03-15	2020-03-09	Bioverativ Therapeutics Inc	Faktor viii-polypeptidformuleringer
AU2014259956A1 (en)	2013-05-01	2015-11-12	Five Prime Therapeutics, Inc.	Methods of treating cancer
WO2014190147A2 (fr)	2013-05-23	2014-11-27	Five Prime Therapeutics, Inc.	Méthodes de traitement du cancer
WO2014186878A1 (fr)	2013-05-24	2014-11-27	Cashman Neil R	Marqueurs de sénescence cellulaire en tant que cibles diagnostiques et thérapeutiques
KR20160010618A (ko)	2013-05-28	2016-01-27	뉴로페이지 파마슈티컬즈, 인크.	감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
CA2915354A1 (fr)	2013-06-14	2014-12-18	President And Fellows Of Harvard College	Modulateurs stabilises du recepteur de l'insuline polypeptidique
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
JP2017501968A (ja)	2013-06-28	2017-01-19	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
SG10201906172XA (en)	2013-07-03	2019-08-27	Alder Biopharmaceuticals Inc	Regulation of glucose metabolism using anti-cgrp antibodies
ES2865473T3 (es)	2013-07-10	2021-10-15	Sutro Biopharma Inc	Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
PE20160671A1 (es)	2013-08-02	2016-07-09	Pfizer	Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
EP3030902B1 (fr)	2013-08-07	2019-09-25	Friedrich Miescher Institute for Biomedical Research	Nouveau procédé de criblage pour traiter l'ataxie de friedreich
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
KR20160042987A (ko)	2013-08-14	2016-04-20	노파르티스 아게	산발성 봉입체 근염을 치료하는 방법
EP4108254A1 (fr)	2013-08-14	2022-12-28	Bioverativ Therapeutics Inc.	Protéines de facteur viii de recombinaison
US20150093399A1 (en)	2013-08-28	2015-04-02	Bioasis Technologies, Inc.	Cns-targeted conjugates having modified fc regions and methods of use thereof
CA2924020A1 (fr)	2013-09-20	2015-03-26	Westfaelische Wilhelms-Universitaet Muenster	Ubiquitine ligases e3 bacteriennes penetrant dans les cellules destinees a etre utilisees en immunotherapie
EP3055298B1 (fr)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
ES2826398T3 (es)	2013-10-15	2021-05-18	Seagen Inc	Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
US10117908B2 (en)	2013-10-17	2018-11-06	Grant Labs, Inc.	Suppression of cellular transformation and dysplasia by topical application of lefty
EP3057605A1 (fr)	2013-10-18	2016-08-24	Novartis AG	Méthodes de traitement du diabete et de troubles associés
US20160272674A1 (en)	2013-11-07	2016-09-22	Abbvie Inc.	Isolation and purification of antibodies
CA2929386C (fr)	2013-11-07	2023-01-03	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anticorps allosteriques de la neureguline, diriges contre her3
WO2015081282A1 (fr)	2013-11-27	2015-06-04	Redwood Bioscience, Inc.	Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
US10325687B2 (en)	2013-12-06	2019-06-18	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
EA201691078A1 (ru)	2013-12-06	2017-01-30	Дана-Фарбер Кэнсер Инститьют, Инк.	Терапевтические пептиды
RS63295B1 (sr)	2013-12-24	2022-06-30	Janssen Pharmaceutica Nv	Anti-vista antitela i fragmenti
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015110923A2 (fr)	2014-01-21	2015-07-30	Acerta Pharma B.V.	Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
US11365447B2 (en)	2014-03-13	2022-06-21	Sequenom, Inc.	Methods and processes for non-invasive assessment of genetic variations
WO2015139020A2 (fr)	2014-03-14	2015-09-17	Dana-Farber Cancer Institute, Inc.	Compositions vaccinales et méthodes pour rétablir la fonction de la voie nkg2d contre les cancers
EA202092926A3 (ru)	2014-03-24	2021-10-29	Биовератив Терапьютикс Инк.	Лиофилизированные составы, содержащие фактор ix
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
PT3151921T (pt)	2014-06-06	2019-11-21	Bristol Myers Squibb Co	Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
MX389695B (es)	2014-06-11	2025-03-20	Kathy A Green	Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
WO2015189816A1 (fr)	2014-06-13	2015-12-17	Friedrich Miescher Institute For Biomedical Research	Nouveau traitement dirigé contre le virus de la grippe
BR112016029624A2 (pt)	2014-06-18	2017-10-24	Csl Behring Gmbh	terapia usando um inibidor do fator xii em um distúrbio neurotraumático
WO2015198202A1 (fr)	2014-06-23	2015-12-30	Friedrich Miescher Institute For Biomedical Research	Méthodes de déclenchement de la formation de novo de l'hétérochromatine et/ou d'inhibition épigénétique avec des petits arn
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2016020880A2 (fr)	2014-08-07	2016-02-11	Novartis Ag	Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
WO2016020882A2 (fr)	2014-08-07	2016-02-11	Novartis Ag	Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
TW201609099A (zh)	2014-08-11	2016-03-16	艾森塔製藥公司	使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
US20170239351A1 (en)	2014-08-11	2017-08-24	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
AU2015305754B2 (en)	2014-08-19	2018-10-25	Merck Sharp & Dohme Llc	Anti-tigit antibodies
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2960642A1 (fr)	2014-09-10	2016-03-17	Georgetown University	Compositions et procedes d'utilisation de l'il4i1 (interleukine-4 induced gene 1)
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
SG11201702606TA (en)	2014-10-03	2017-04-27	Massachusetts Inst Technology	Antibodies that bind ebola glycoprotein and uses thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
SMT202100388T1 (it)	2014-10-24	2021-09-14	Bristol Myers Squibb Co	Polipeptidi fgf-21 modificati e loro usi
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
MY189836A (en)	2014-11-21	2022-03-11	Bristol Myers Squibb Co	Antibodies against cd73 and uses thereof
JP6668345B2 (ja)	2014-11-21	2020-03-18	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	修飾された重鎖定常領域を含む抗体
PL3227313T3 (pl)	2014-12-03	2022-05-09	Proclara Biosciences, Inc.	Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji
JP2018505911A (ja)	2014-12-05	2018-03-01	イミュネクスト，インコーポレーテッド	推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
JP6864953B2 (ja)	2014-12-09	2021-04-28	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ａｘｌに対するヒトモノクローナル抗体
CN113563468A (zh)	2014-12-19	2021-10-29	雷根尼桑斯公司	结合人c6的抗体及其用途
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3835319B1 (fr)	2014-12-19	2025-11-19	H. Lundbeck A/S	Anticorps anti-acth humanisés et leur utilisation
CN107207594B (zh)	2014-12-23	2019-05-07	百时美施贵宝公司	针对tigit的抗体
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
WO2016128912A1 (fr)	2015-02-12	2016-08-18	Acerta Pharma B.V.	Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1, et/ou d'un inhibiteur de pd-l1
ES3011733T3 (en)	2015-02-13	2025-04-08	Transgene	Immunotherapeutic vaccine and antibody combination therapy
WO2016131893A1 (fr)	2015-02-18	2016-08-25	Medimmune Limited	Polypeptides de fusion de l'incrétine
US10227408B2 (en)	2015-02-19	2019-03-12	Compugen Ltd.	Anti-PVRIG antibodies and methods of use
WO2016135041A1 (fr)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
WO2016167291A1 (fr)	2015-04-13	2016-10-20	国立研究開発法人産業技術総合研究所	Cytokine cyclisée et son procédé de production
JP6770533B2 (ja)	2015-05-22	2020-10-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｃａｔｈ−Ｄの触媒活性と、そのＬＲＰ１レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
TW201702272A (zh)	2015-05-22	2017-01-16	美國紀念斯隆凱特琳癌症中心	Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
TN2019000101A1 (en)	2015-05-29	2020-07-15	Bristol Myers Squibb Co	Antibodies against ox40 and uses thereof.
CA2982237A1 (fr)	2015-06-05	2016-12-08	Novartis Ag	Anticorps ciblant la proteine morphogenetique osseuse 9 (bmp9) et methodes associees
TWI726889B (zh)	2015-06-10	2021-05-11	英商梅迪繆思有限公司	蛋白酶抗性之脂化肽
WO2016207717A1 (fr)	2015-06-24	2016-12-29	Janssen Pharmaceutica Nv	Anticorps et fragments anti-vista
UY36751A (es)	2015-06-26	2017-01-31	Novartis Ag	Anticuerpos de factor xi y métodos de uso
AU2016285920A1 (en)	2015-06-29	2018-02-01	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
US20180201687A1 (en)	2015-07-07	2018-07-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to myosin 18a and uses thereof
DK3322733T3 (da)	2015-07-13	2021-10-18	Compugen Ltd	Hide1-sammensætninger og fremgangsmåder
IL274572B2 (en)	2015-07-16	2024-01-01	Biolinerx Ltd	Compositions and methods for treating cancer
EP3328994A4 (fr)	2015-07-31	2019-04-17	Memorial Sloan-Kettering Cancer Center	Protéines de liaison d'antigène ciblant cd56 et leurs utilisations
AU2016303688B2 (en)	2015-07-31	2023-06-15	Research Institute At Nationwide Children's Hospital	Peptides and antibodies for the removal of biofilms
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3185706C (fr)	2015-08-03	2025-11-18	Novartis Ag	Methode de traitement des troubles associes au fgf21
CN107921103A (zh)	2015-08-12	2018-04-17	细胞机械股份有限公司	涉及长半衰期凝血复合物的方法和组合物
US20190008859A1 (en)	2015-08-21	2019-01-10	Acerta Pharma B.V.	Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
KR20250073532A (ko)	2015-09-02	2025-05-27	이뮤텝 에스.에이.에스.	항-lag-3 항체
JP6516925B2 (ja)	2015-09-09	2019-05-22	ノバルティスアーゲー	胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
AU2016320748B2 (en)	2015-09-09	2019-05-02	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
ES2980794T3 (es)	2015-09-15	2024-10-03	Acerta Pharma Bv	Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
US20190022092A1 (en)	2015-09-15	2019-01-24	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
WO2017049082A2 (fr)	2015-09-17	2017-03-23	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Compositions comprenant des glycoprotéines spécifiques de grossesse et leurs procédés d'utilisation
WO2017059371A1 (fr)	2015-10-01	2017-04-06	Amgen Inc.	Traitement de troubles liés à l'acide biliaire
WO2017066719A2 (fr)	2015-10-14	2017-04-20	Research Institute At Nationwide Children's Hospital	Agents spécifiques interférant avec hu
WO2017066714A1 (fr)	2015-10-16	2017-04-20	Compugen Ltd.	Conjugués d'anticorps anti-vsig1 et de médicaments
WO2017072669A1 (fr)	2015-10-28	2017-05-04	Friedrich Miescher Institute For Biomedical Research	Ténascine w et cancers du tractus biliaire
JO3555B1 (ar)	2015-10-29	2020-07-05	Merck Sharp & Dohme	جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
DK3368571T5 (da)	2015-10-30	2024-09-30	Univ California	Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
KR102783230B1 (ko)	2015-11-09	2025-03-19	알.피.쉐러 테크놀러지즈 엘엘씨	항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
BR112018010172A2 (pt)	2015-11-19	2018-11-21	Bristol Myers Squibb Co	anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
WO2017095875A1 (fr)	2015-11-30	2017-06-08	Bristol-Myers Squibb Company	Anticorps anti ip-10 humaine et leurs utilisations
US11793880B2 (en)	2015-12-04	2023-10-24	Seagen Inc.	Conjugates of quaternized tubulysin compounds
CN108367043A (zh)	2015-12-04	2018-08-03	西雅图基因公司	季铵化的微管溶素化合物的缀合物
KR20180086502A (ko)	2015-12-16	2018-07-31	머크 샤프 앤드 돔 코포레이션	항-lag3 항체 및 항원-결합 단편
EP3389711A1 (fr)	2015-12-18	2018-10-24	Novartis AG	Anticorps ciblant cd32b et leurs procédés d'utilisation associés
CN116003593A (zh)	2016-01-11	2023-04-25	苏黎世大学	针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
HUE052893T2 (hu)	2016-01-13	2021-05-28	Acerta Pharma Bv	Antifolát és BTK-gátló terápiás kombinációi
US11505599B2 (en)	2016-01-14	2022-11-22	Memorial Sloan-Kettering Cancer Center	T cell receptor-like antibodies specific for Foxp3-derived peptides
US10899836B2 (en)	2016-02-12	2021-01-26	Janssen Pharmaceutica Nv	Method of identifying anti-VISTA antibodies
CN109310733A (zh)	2016-02-23	2019-02-05	百欧林纳克斯有限公司	治疗急性骨髓性白血病的方法
US20230183346A1 (en)	2016-02-26	2023-06-15	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies having specificity for btla and uses thereof
ES2985566T3 (es)	2016-03-04	2024-11-06	Univ Rockefeller	Anticuerpos contra CD40 con actividad agonista mejorada
KR20230038311A (ko)	2016-03-04	2023-03-17	브리스톨-마이어스 스큅 컴퍼니	항-cd73 항체와의 조합 요법
AR107890A1 (es)	2016-03-10	2018-06-28	Medimmune Ltd	Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
US11020160B2 (en)	2016-03-21	2021-06-01	Warsaw Orthopedic, Inc.	Surgical injection system and method
EP4509180A3 (fr)	2016-03-22	2025-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps humanisés anti-claudine-1 et utilisations correspondantes
KR20180134351A (ko)	2016-03-25	2018-12-18	시애틀 지네틱스, 인크.	페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
EA201892249A1 (ru)	2016-04-04	2019-05-31	Шайр Хьюман Дженетик Терапиз, Инк.	Конъюгированный ингибитор c1-эстеразы и пути его применения
EP3440107A4 (fr)	2016-04-06	2020-02-19	CSL Limited	Méthode de traitement de l'athérosclérose
KR102466763B1 (ko)	2016-04-13	2022-11-11	오리맵스 리미티드	항- psma 항체 및 이의 용도
CN109789201B (zh)	2016-04-15	2023-06-16	伊穆奈克斯特股份有限公司	抗人vista抗体及其用途
EP3426288A4 (fr)	2016-04-15	2019-10-30	Alder Biopharmaceuticals, Inc.	Anticorps anti-pacap et leurs utilisations
EP4610656A3 (fr)	2016-04-15	2025-11-19	Beckman Coulter, Inc.	Macromolécules photoactives et leurs utilisations
CA3019588A1 (fr)	2016-04-20	2017-10-26	Merck Sharp & Dohme Corp.	Proteines de liaison a un antigene de neutralisation des cmv
US10709814B2 (en)	2016-04-22	2020-07-14	Warsaw Orthopedic, Inc.	Osteoimplant comprising an insoluble fibrous polymer
ES2981471T3 (es)	2016-04-25	2024-10-09	Five Prime Therapeutics Inc	NOPE para el tratamiento de la pérdida de masa muscular y la debilidad muscular patológicas
WO2017189724A1 (fr)	2016-04-27	2017-11-02	Novartis Ag	Anticorps dirigés contre le facteur de différenciation de croissance 15 et leurs utilisations
WO2017201731A1 (fr)	2016-05-27	2017-11-30	Beijing Vdjbio Co., Ltd.	Anticorps, composition et kits les comprenant et leurs procédés d'utilisation
EP3471759A1 (fr)	2016-06-15	2019-04-24	Novartis AG	Méthodes de traitement de maladie à l'aide d'inhibiteurs de la protéine morphogénétique osseuse 6 (bmp6)
MY200602A (en)	2016-07-14	2024-01-04	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
BR112019001693A2 (pt)	2016-07-29	2019-07-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	anticorpos direcionados a macrófagos associados a tumores e seus usos
NL2017267B1 (en)	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
CN110088132B (zh)	2016-08-17	2020-10-27	康姆普根有限公司	抗tigit抗体，抗pvrig抗体及其组合
WO2018044970A1 (fr)	2016-08-31	2018-03-08	University Of Rochester	Anticorps monoclonaux humains dirigés contre l'enveloppe du rétrovirus endogène humain k (herv-k) et leurs utilisations
JP2019530440A (ja)	2016-09-02	2019-10-24	ザリージェンツオブザユニバーシティオブカリフォルニア	インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
SG10201912925SA (en)	2016-10-13	2020-02-27	Massachusetts Inst Technology	Antibodies that bind zika virus envelope protein and uses thereof
TWI788307B (zh)	2016-10-31	2023-01-01	美商艾歐凡斯生物治療公司	用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en)	2016-11-17	2022-08-02	Iovance Biotherapeutics, Inc.	Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
US20230192896A1 (en)	2016-11-23	2023-06-22	Bioverativ Therapeutics Inc.	Bispecific antibodies binding to coagulation factor ix and coagulation factor x
IL319473A (en)	2016-12-02	2025-05-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN110520149A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	诱导对凝血因子的免疫耐受性的方法
KR20230159629A (ko)	2016-12-12	2023-11-21	벡톤 디킨슨 앤드 컴퍼니	수용성 중합체 염료
JP7244987B2 (ja)	2016-12-14	2023-03-23	シージェンインコーポレイテッド	多剤抗体薬物コンジュゲート
CN110325211A (zh)	2016-12-23	2019-10-11	诺华股份有限公司	采用抗因子XI/XIa抗体治疗的方法
IL267538B2 (en)	2016-12-23	2024-05-01	Novartis Ag	Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
AU2018206560B9 (en)	2017-01-04	2025-04-03	Research Institute At Nationwide Children's Hospital	Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja)	2017-01-04	2024-07-11	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
BR112019013940A2 (pt)	2017-01-06	2020-02-11	Iovance Biotherapeutics, Inc.	Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
CA3049165A1 (fr)	2017-01-06	2018-07-12	Iovance Biotherapeutics, Inc.	Expansion de lymphocytes infiltrant les tumeurs avec des agonistes des canaux potassiques et leurs utilisations therapeutiques
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (fr)	2017-01-09	2018-07-12	Shuttle Pharmaceuticals, Llc	Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine
WO2018138267A1 (fr)	2017-01-27	2018-08-02	Cinfa Biotech S.L.	Procede de determination de l'efficacite d'une composition comprenant le g-csf
CA3051862A1 (fr)	2017-01-31	2018-08-09	Bioverativ Therapeutics Inc.	Proteine de fusion du facteur ix et procedes de fabrication et d'utilisation associes
CN110637027B (zh)	2017-02-08	2024-08-30	百时美施贵宝公司	包含药代动力学增强子的修饰的松弛素多肽及其用途
US10899844B2 (en)	2017-02-08	2021-01-26	Novartis Ag	FGF21 mimetic antibodies and uses thereof
CN110506057B (zh)	2017-02-17	2023-09-29	百时美施贵宝公司	Alpha突触核蛋白抗体及其应用
US11274160B2 (en)	2017-03-02	2022-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to Nectin-4 and uses thereof
AU2018236271B2 (en)	2017-03-15	2023-12-21	Research Institute At Nationwide Children's Hospital	Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2018237683A1 (en)	2017-03-24	2019-10-31	Seagen Inc.	Process for the preparation of glucuronide drug-linkers and intermediates thereof
FI3600415T3 (fi)	2017-03-24	2025-12-05	Novartis Ag	Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
TWI796329B (zh)	2017-04-07	2023-03-21	美商默沙東有限責任公司	抗－ilt4抗體及抗原結合片段
CN118267470A (zh)	2017-04-13	2024-07-02	赛罗帕私人有限公司	抗SIRPα抗体
US10294264B2 (en)	2017-04-21	2019-05-21	Warsaw Orthopedic, Inc.	Oxysterol-therapeutic agent derivative for bone healing
US20200224161A1 (en)	2017-05-10	2020-07-16	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3625251A1 (fr)	2017-05-15	2020-03-25	University Of Rochester	Anticorps monoclonal anti-virus de la grippe à large neutralisation et utilisations associées
IL270596B2 (en)	2017-05-25	2026-01-01	Bristol Myers Squibb Co	Antibodies containing heavy constant regions are adapted for use in cancer therapy
CN110799213A (zh)	2017-06-01	2020-02-14	康姆普根有限公司	三联组合抗体疗法
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018229715A1 (fr)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
EP3664828A1 (fr)	2017-08-10	2020-06-17	Friedrich Miescher Institute for Biomedical Research	Hdac6 et agrégation de protéines
KR102764182B1 (ko)	2017-09-21	2025-02-07	임체크 테라퓨틱스	Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
EP3694552A1 (fr)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anticorps anti-lap et leurs utilisations
EP3700933A1 (fr)	2017-10-25	2020-09-02	Novartis AG	Anticorps ciblant cd32b et leurs procédés d'utilisation
EP3714041A1 (fr)	2017-11-22	2020-09-30	Iovance Biotherapeutics, Inc.	Expansion de lymphocytes de sang périphérique (pbl) à partir de sang périphérique
EP3724885A2 (fr)	2017-12-15	2020-10-21	Iovance Biotherapeutics, Inc.	Systèmes et procédés pour déterminer l'administration bénéfique de lymphocytes infiltrant les tumeurs et leurs procédés d'utilisation, et administration bénéfique de lymphocytes infiltrant les tumeurs et ses procédés d'utilisation
CN119286279A (zh)	2017-12-26	2025-01-10	贝克顿·迪金森公司	深紫外线可激发的水溶剂化聚合物染料
WO2019129137A1 (fr)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Anticorps anti-lag-3 et utilisations associées
WO2019129136A1 (fr)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Anticorps anti-pd-l1 et ses applications
CN111788227B (zh)	2017-12-27	2025-02-25	百时美施贵宝公司	抗cd40抗体及其用途
CN115925943A (zh)	2017-12-27	2023-04-07	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
KR20250078626A (ko)	2018-01-12	2025-06-02	브리스톨-마이어스 스큅 컴퍼니	Tim3에 대한 항체 및 그의 용도
WO2019148412A1 (fr)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anticorps bispécifiques anti-pd-1/lag3
CA3090795A1 (fr)	2018-02-13	2019-08-22	Iovance Biotherapeutics, Inc.	Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du recepteur a2a de l'adenosine et combinaisons therapeutiques de til et d'antagonistes du recepteur a2 a de l'adenosine
NL2020520B1 (en)	2018-03-02	2019-09-12	Labo Bio Medical Invest B V	Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
BR112020019083A2 (pt)	2018-03-21	2020-12-29	Five Prime Therapeutics, Inc.	Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210665A1 (es)	2018-03-23	2021-03-31	Bristol Myers Squibb Co	Anticuerpos contra mica y/o micb y sus usos
CN119220109A (zh)	2018-03-30	2024-12-31	贝克顿·迪金森公司	含侧基发色团的水溶性聚合染料
EP3552631A1 (fr)	2018-04-10	2019-10-16	Inatherys	Conjugués d'anticorps-médicament et leurs utilisations pour le traitement du cancer
EP3787678A1 (fr)	2018-05-03	2021-03-10	University Of Rochester	Anticorps monoclonaux de la neuraminidase anti-grippe et leurs utilisations
SI3793586T1 (sl)	2018-05-16	2024-07-31	Csl Limited	Različice receptorja za topni komplement tipa 1 in njihova uporaba
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
TWI851577B (zh)	2018-06-07	2024-08-11	美商思進公司	喜樹鹼結合物
TW202428604A (zh)	2018-07-09	2024-07-16	美商戊瑞治療有限公司	結合至ilt4的抗體
BR112021000303A2 (pt)	2018-07-11	2021-04-13	Five Prime Therapeutics, Inc.	Anticorpos que se ligam a vista em ph ácido
US20220162336A1 (en)	2018-07-22	2022-05-26	Bioasis Technologies, Inc.	Treatment of lymphatic metastases
KR20210040827A (ko)	2018-07-25	2021-04-14	이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드	항 tigit 항체 및 그 용도
HRP20260034T1 (hr)	2018-08-01	2026-02-27	Imcheck Therapeutics	Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja
TW202031273A (zh)	2018-08-31	2020-09-01	美商艾歐凡斯生物治療公司	抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
HRP20240016T1 (hr)	2018-09-11	2024-03-29	Ambrx, Inc.	Konjugati polipeptida interleukina-2 i njihove uporabe
CA3112599A1 (fr)	2018-09-20	2020-03-26	Iovance Biotherapeutics, Inc.	Expansion de til a partir d'echantillons de tumeur cryoconserves
JP7541513B2 (ja)	2018-10-05	2024-08-28	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	細菌バイオフィルムの酵素的破壊のための組成物および方法
EP3863722A2 (fr)	2018-10-10	2021-08-18	Tilos Theapeutics, Inc.	Variants d'anticorps anti-lap et leurs utilisations
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
WO2020082057A1 (fr)	2018-10-19	2020-04-23	Ambrx, Inc.	Conjugués polypeptidiques d'interleukine-10, dimères de ceux-ci et leurs utilisations
KR20210124179A (ko)	2018-11-02	2021-10-14	베이징 브이디제이바이오 컴퍼니 리미티드	변형된 ctla4 및 이의 사용 방법
TW202039831A (zh)	2018-11-05	2020-11-01	美商艾歐凡斯生物治療公司	對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
CA3118493A1 (fr)	2018-11-05	2020-05-14	Iovance Biotherapeutics, Inc.	Expansion de til utilisant des inhibiteurs de la voie akt
US11274150B2 (en)	2018-11-16	2022-03-15	Bristol-Myers Squibb Company	Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
EP3887393A1 (fr)	2018-11-26	2021-10-06	Novartis AG	Polypeptides de fusion de lpl-gpihbp1
EP3887397A1 (fr)	2018-11-28	2021-10-06	Bristol-Myers Squibb Company	Anticorps comprenant des régions constantes de chaîne lourde modifiées
US20220112557A1 (en)	2019-01-10	2022-04-14	Iovance Biotherapeutics, Inc.	System and methods for monitoring adoptive cell therapy clonality and persistence
CN109762067B (zh)	2019-01-17	2020-02-28	北京天广实生物技术股份有限公司	结合人Claudin 18.2的抗体及其用途
US11008395B2 (en)	2019-01-22	2021-05-18	Bristol Myers-Squibb Company	Antibodies against IL-7R alpha subunit and uses thereof
TWI756621B (zh)	2019-01-25	2022-03-01	大陸商信達生物製藥（蘇州）有限公司	新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
JP7695885B2 (ja)	2019-02-12	2025-06-19	アンブルックス，インコーポレイテッド	抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
US20220133795A1 (en)	2019-03-01	2022-05-05	Iovance Biotherapeutics, Inc.	Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
US10570210B1 (en)	2019-03-04	2020-02-25	Beijing Mabworks Biotech Co.Ltd	Antibodies binding CD40 and uses thereof
AU2020243076A1 (en)	2019-03-20	2021-10-14	Centre National De La Recherche Scientifique - Cnrs -	Antibodies having specificity for BTN2 and uses thereof
CN113631573B (zh)	2019-03-25	2024-06-04	国家医疗保健研究所	抗Tau抗体及其在制备用于治疗疾病的药物中的用途
EP3972997A1 (fr)	2019-05-20	2022-03-30	Institut National de la Santé et de la Recherche Médicale (INSERM)	Nouveaux anticorps anti-cd25
EP3972993A1 (fr)	2019-05-21	2022-03-30	Novartis AG	Domaines de cd58 variants et leurs utilisations
PE20220568A1 (es)	2019-05-21	2022-04-20	Novartis Ag	Moleculas de union a cd19 y usos de las mismas
EA202193345A1 (ru)	2019-06-12	2022-03-16	Новартис Аг	Антитела к рецептору-1 натрийуретического пептида и способы их применения
WO2021007260A2 (fr)	2019-07-08	2021-01-14	Research Institute At Nationwide Children's Hospital	Compositions d'anticorps pour détruire des biofilms
CN114144436A (zh)	2019-07-24	2022-03-04	H.隆德贝克有限公司	抗mGluR5抗体及其用途
KR20220041881A (ko)	2019-07-29	2022-04-01	컴퓨젠 엘티디.	항-pvrig 항체 제제 및 이의 용도
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
EP4031575A1 (fr)	2019-09-19	2022-07-27	Bristol-Myers Squibb Company	Anticorps se liant à vista à un ph acide
WO2021058729A1 (fr)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations
EP4034560A1 (fr)	2019-09-27	2022-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps de de substance inhibitrice müllérienne et leurs utilisations
AU2020356955A1 (en)	2019-10-04	2022-04-14	Seagen Inc.	Camptothecin peptide conjugates
TW202128160A (zh)	2019-10-18	2021-08-01	美國加利福尼亞大學董事會	用於治療病原性血管病症之方法及組合物
CN114980922A (zh)	2019-11-04	2022-08-30	康姆普根有限公司	抗pvrig抗体制剂和抗pd-1抗体的组合疗法
US12577324B2 (en)	2019-12-09	2026-03-17	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies having specificity to HER4 and uses thereof
JP7456075B2 (ja)	2020-01-03	2024-03-27	ビオシオンインコーポレイテッド	抗体結合ｂｃｍａ及びその使用
US20230105029A1 (en)	2020-02-27	2023-04-06	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Antibodies binding il4r and uses thereof
WO2021175954A1 (fr)	2020-03-04	2021-09-10	Imcheck Therapeutics Sas	Anticorps ayant une spécificité pour btnl8 et leurs utilisations
WO2021183832A1 (fr)	2020-03-11	2021-09-16	Ambrx, Inc.	Conjugués polypeptidiques d'interleukine-2 et leurs procédés d'utilisation
WO2021202235A1 (fr)	2020-04-01	2021-10-07	University Of Rochester	Anticorps monoclonaux contre l'hémagglutinine (ha) et la neuraminidase (na) des virus de la grippe h3n2
KR20210124867A (ko)	2020-04-06	2021-10-15	하. 룬드벡 아크티에셀스카브	항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
EP4132971A1 (fr)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Anticorps anti-lap à maturation d'affinité et leurs utilisations
WO2021207701A1 (fr)	2020-04-10	2021-10-14	Seagen Inc.	Lieurs de variants de charge
MX2021015024A (es)	2020-04-28	2022-01-18	Univ Rockefeller	Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
EP4143227A2 (fr)	2020-04-30	2023-03-08	Sairopa B.V.	Anticorps anti-cd103
JP2023525053A (ja)	2020-05-12	2023-06-14	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
MX2022014243A (es)	2020-05-12	2022-12-02	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Proteina de union al antigeno st2.
WO2021231732A1 (fr)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Anticorps anti-garp
US20210355468A1 (en)	2020-05-18	2021-11-18	Bioasis Technologies, Inc.	Compositions and methods for treating lewy body dementia
US20210393787A1 (en)	2020-06-17	2021-12-23	Bioasis Technologies, Inc.	Compositions and methods for treating frontotemporal dementia
JP2023530187A (ja)	2020-06-22	2023-07-13	イノベントバイオロジクス（スーチョウ）カンパニー，リミティド	抗ａｎｇ－２抗体とその用途
CA3183835A1 (fr)	2020-06-25	2021-12-30	Jeanne E. Baker	Anticorps a haute affinite ciblant la proteine tau phosphorylee a la position 413 de serine
KR20230030644A (ko)	2020-06-29	2023-03-06	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
EP4199968A1 (fr)	2020-08-20	2023-06-28	Ambrx, Inc.	Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci
US20230365680A1 (en)	2020-09-30	2023-11-16	Compugen Ltd.	Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2022076606A1 (fr)	2020-10-06	2022-04-14	Iovance Biotherapeutics, Inc.	Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
US20230372397A1 (en)	2020-10-06	2023-11-23	Iovance Biotherapeutics, Inc.	Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4232822A2 (fr)	2020-10-26	2023-08-30	Compugen Ltd.	Pvrl2 et/ou pvrig en tant que biomarqueurs de traitement
TW202227481A (zh)	2020-11-04	2022-07-16	美國洛克菲勒大學	中和抗sars-cov-2抗體
US20240025993A1 (en)	2020-11-06	2024-01-25	Novartis Ag	Cd19 binding molecules and uses thereof
WO2022106663A1 (fr)	2020-11-20	2022-05-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps anti-cd25
EP4247497A1 (fr)	2020-11-20	2023-09-27	Institut National de la Santé et de la Recherche Médicale (INSERM)	Anticorps anti-cd25
TW202241468A (zh)	2020-12-11	2022-11-01	美商艾歐凡斯生物治療公司	用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
EP4259661A1 (fr)	2020-12-14	2023-10-18	Novartis AG	Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
CA3202483A1 (fr)	2020-12-17	2022-06-23	Maria Fardis	Traitement avec des therapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de ctla-4 et de pd-1
US20240123067A1 (en)	2020-12-17	2024-04-18	Iovance Biotherapeutics, Inc.	Treatment of cancers with tumor infiltrating lymphocyte therapies
CN114685669A (zh)	2020-12-30	2022-07-01	和铂医药(苏州)有限公司	结合trop2的抗体及其用途
TW202242085A (zh)	2020-12-31	2022-11-01	美商艾歐凡斯生物治療公司	供自動生產腫瘤浸潤淋巴球的裝置和方法
TW202246242A (zh)	2021-01-15	2022-12-01	美商西健公司	免疫調節抗體藥物結合物
JP2024505636A (ja)	2021-01-15	2024-02-07	ザロックフェラーユニバーシティー	抗ｓａｒｓ－ｃｏｖ－２中和抗体
WO2022165275A2 (fr)	2021-01-28	2022-08-04	Compugen Ltd.	Polythérapie comprenant des formulations d'anticorps anti-pvs et des anticorps anti-pd-1
EP4284516A1 (fr)	2021-01-28	2023-12-06	Compugen Ltd.	Formulations d'anticorps anti-pvrig et leurs utilisations
TW202241508A (zh)	2021-01-29	2022-11-01	美商艾歐凡斯生物治療公司	細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
AU2022216598A1 (en)	2021-02-03	2023-08-03	Regents Of The University Of Minnesota	Immunostimulatory compounds and conjugates
CN116848142A (zh)	2021-02-04	2023-10-03	信达生物制药(苏州)有限公司	抗tnfr2抗体及其用途
WO2022187741A2 (fr)	2021-03-05	2022-09-09	Iovance Biotherapeutics, Inc.	Stockage de tumeur et compositions de culture cellulaire
AU2022238571A1 (en)	2021-03-18	2023-09-14	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
WO2022198141A1 (fr)	2021-03-19	2022-09-22	Iovance Biotherapeutics, Inc.	Procédés pour la multiplication des lymphocytes infiltrant les tumeurs (til) liés à la sélection de cd39/cd69 et inactivation de gènes dans les til
AR125199A1 (es)	2021-03-23	2023-06-21	Iovance Biotherapeutics Inc	Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
AU2022246174A1 (en)	2021-03-25	2023-09-14	Iovance Biotherapeutics, Inc.	Methods and compositions for t-cell coculture potency assays and use with cell therapy products
US20250161471A1 (en)	2021-04-03	2025-05-22	Feng Tian	Anti-her2 antibody-drug conjugates and uses thereof
EP4326287A2 (fr)	2021-04-19	2024-02-28	Iovance Biotherapeutics, Inc.	Récepteurs costimulateurs chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires
US20240336672A1 (en)	2021-04-26	2024-10-10	Institut Pasteur	Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
WO2022235867A2 (fr)	2021-05-06	2022-11-10	The Rockefeller University	Anticorps neutralisant anti-sars-cov-2 et leurs procédés d'utilisation
US20220372114A1 (en)	2021-05-17	2022-11-24	Curia Ip Holdings, Llc	Sars-cov-2 spike protein antibodies
WO2022245754A1 (fr)	2021-05-17	2022-11-24	Iovance Biotherapeutics, Inc.	Lymphocytes infiltrant les tumeurs modifiés par un gène pd-1 et leurs utilisations en immunothérapie
US20230115257A1 (en)	2021-05-17	2023-04-13	Curia Ip Holdings, Llc	Sars-cov-2 spike protein antibodies
CA3221398A1 (fr)	2021-05-28	2022-12-01	Seagen Inc.	Conjugues d'anticorps d'anthracycline
TW202313974A (zh)	2021-06-08	2023-04-01	瑞典商阿斯特捷利康公司	用於治療肝病之組合療法
CN117480183A (zh)	2021-06-18	2024-01-30	正大天晴药业集团股份有限公司	抗il-36r抗体及其用途
WO2022269451A1 (fr)	2021-06-22	2022-12-29	Novartis Ag	Anticorps bispécifiques destinés à être utilisés dans le traitement de l'hidrosadénite suppurée
EP4588524A3 (fr)	2021-07-01	2025-09-03	Compugen Ltd.	Anti-tigit et anti-pvrig dans des traitements de monothérapie et de combinaison
US20240365776A1 (en)	2021-07-22	2024-11-07	Iovance Biotherapeutics, Inc	Method for cryopreservation of solid tumor fragments
US20240342285A1 (en)	2021-07-28	2024-10-17	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
EP4392447A1 (fr)	2021-08-27	2024-07-03	H. Lundbeck A/S	Traitement de la céphalée vasculaire de horton à l'aide d'anticorps anti-cgrp
IL311333A (en)	2021-09-09	2024-05-01	Iovance Biotherapeutics Inc	Processes for generating til products using pd-1 talen knockdown
EP4404969A1 (fr)	2021-09-24	2024-07-31	Iovance Biotherapeutics, Inc.	Processus d'expansion et agents pour lymphocytes infiltrant la tumeur
EP4155349A1 (fr)	2021-09-24	2023-03-29	Becton, Dickinson and Company	Colorants absorbants jaunes verts solubles dans l'eau
CN118541392A (zh)	2021-09-28	2024-08-23	准星生物医药有限公司	多种形式的分子复合物
WO2023052541A1 (fr)	2021-09-30	2023-04-06	Imcheck Therapeutics	Combinaison d'un anticorps d'activation anti-btn3a et d'un agoniste il-2 en vue d'une utilisation en thérapie
US20250339522A1 (en)	2021-10-15	2025-11-06	Compugen Ltd.	Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2023077015A2 (fr)	2021-10-27	2023-05-04	Iovance Biotherapeutics, Inc.	Systèmes et méthodes pour coordonner la fabrication de cellules pour l'immunothérapie spécifique d'un patient
JP2024539893A (ja)	2021-10-27	2024-10-31	イムチェックセラピューティクスエスエーエス	感染性障害を治療する方法で使用するためのブチロフィリン（ｂｔｎ）３ａ活性化抗体
TW202339803A (zh)	2021-11-09	2023-10-16	德商圖布里斯有限公司	包含磷(v)及喜樹鹼分子部分的共軛物
CN118302197A (zh)	2021-11-09	2024-07-05	Tubulis 股份有限公司	包含磷(v)和药物部分的偶联物
EP4430167A1 (fr)	2021-11-10	2024-09-18	Iovance Biotherapeutics, Inc.	Procédés de traitement de multiplication utilisant des lymphocytes infiltrant les tumeurs cd8
PE20241755A1 (es)	2021-11-19	2024-08-28	Mirobio Ltd	Anticuerpos pd-1 disenados por ingenieria y usos de estos
US20260070974A1 (en)	2021-11-25	2026-03-12	Nona Biosciences (Suzhou) Co., Ltd.	Anti-siglec-15 antibody and use thereof
EP4469159A1 (fr)	2022-01-27	2024-12-04	The Rockefeller University	Anticorps anti-sars-cov-2 largement neutralisants ciblant le domaine n-terminal de la protéine de spicule et leurs procédés d'utilisation
WO2023147488A1 (fr)	2022-01-28	2023-08-03	Iovance Biotherapeutics, Inc.	Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine
US20250101380A1 (en)	2022-01-28	2025-03-27	Iovance Biotherapeutics, Inc.	Tumor infiltrating lymphocytes engineered to express payloads
US20250179175A1 (en)	2022-03-09	2025-06-05	Alderaan Biotechnology	Anti-cd160 transmembrane isoform antibodies
CR20240375A (es)	2022-03-11	2025-01-06	Mablink Bioscience	Conjugados anticuerpo-fármaco y sus usos
PE20251671A1 (es)	2022-03-15	2025-06-30	Compugen Ltd	Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
IL315508A (en)	2022-03-17	2024-11-01	Seagen Inc	Camptothecin conjugates
WO2023173393A1 (fr)	2022-03-18	2023-09-21	北京天广实生物技术股份有限公司	Anticorps se liant à b7-h3 et son utilisation
US20240103010A1 (en)	2022-03-18	2024-03-28	Compugen Ltd.	Pvrl2 and/or pvrig as biomarkers for treatment
WO2023187657A1 (fr)	2022-03-30	2023-10-05	Novartis Ag	Méthodes de traitement de troubles à l'aide d'anticorps anti-récepteur du peptide natriurétique 1 (npr1)
EP4504220A1 (fr)	2022-04-06	2025-02-12	Iovance Biotherapeutics, Inc.	Traitement de patients souffrant de cpnpc avec des thérapies lymphocytaires infiltrant les tumeurs
PE20251170A1 (es)	2022-04-06	2025-04-23	Mirobio Ltd	Anticuerpos cd200r disenados por ingenieria y usos de estos
CA3248034A1 (fr)	2022-04-15	2023-10-19	Iovance Biotherapeutics, Inc.	Procédés d’expansion des cellules til au moyen de combinaisons de cytokines spécifiques et/ou d’un traitement par inhibiteur d’akt
WO2023215740A1 (fr)	2022-05-06	2023-11-09	Seagen Inc.	Conjugués anticorps-médicament immunomodulateurs
EP4522202A1 (fr)	2022-05-10	2025-03-19	Iovance Biotherapeutics, Inc.	Traitement de patients atteints d'un cancer avec des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un agoniste d'il-15r
US20250353909A1 (en)	2022-05-10	2025-11-20	Imcheck Therapeutics	Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders
EP4547759A2 (fr)	2022-07-01	2025-05-07	Beckman Coulter, Inc.	Nouveaux colorants fluorescents et polymères issus de dérivés de dihydrophenanthrène
US20260008990A1 (en)	2022-07-06	2026-01-08	Iovance Biotherapeutics, Inc.	Devices and processes for automated production of tumor infiltrating lymphocytes
AR129991A1 (es)	2022-07-22	2024-10-23	Bristol Myers Squibb Co	Anticuerpos que se unen a la pad4 humana y usos de los mismos
US20260035460A1 (en)	2022-07-28	2026-02-05	Adeboye Henry ADEWOYE, MD	Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
EP4565683A1 (fr)	2022-08-01	2025-06-11	Iovance Biotherapeutics, Inc.	Récepteurs de costimulation chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires
IL318450A (en)	2022-08-03	2025-03-01	Seagen Inc	Immunostimulatory ANTI-PD-L1-Drug conjugates
US11773160B1 (en)	2022-08-05	2023-10-03	Anaveon AG	Immune-stimulating IL-2 fusion proteins
EP4321522A1 (fr)	2022-08-12	2024-02-14	Seagen Inc.	Composés cytotoxiques et conjugués de ceux-ci
WO2024044327A1 (fr)	2022-08-26	2024-02-29	Beckman Coulter, Inc.	Monomères dhnt et colorants polymères ayant des propriétés photophysiques modifiées
EP4584291A1 (fr)	2022-09-08	2025-07-16	Institut National de la Santé et de la Recherche Médicale	Anticorps présentant une spécificité pour ltbp2 et leurs utilisations
US20260035468A1 (en)	2022-09-12	2026-02-05	Institut National de la Santé et de la Recherche Médicale	New anti-itgb8 antibodies and its uses thereof
WO2024074498A1 (fr)	2022-10-04	2024-04-11	Imcheck Therapeutics	Combinaison d'un anticorps d'activation de btn3a, d'un inhibiteur de bcl2 et d'un agent d'hypométhylation destinée à être utilisée dans le traitement du cancer
US20240190958A1 (en)	2022-10-18	2024-06-13	Tubulis Gmbh	Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
WO2024083953A1 (fr)	2022-10-18	2024-04-25	Tubulis Gmbh	Nouvel anticorps anti-tpbg et conjugués anticorps-médicament basés sur celui-ci, procédés thérapeutiques et utilisations dudit anticorps
WO2024098027A1 (fr)	2022-11-04	2024-05-10	Iovance Biotherapeutics, Inc.	Procédés d'expansion de lymphocytes infiltrant les tumeurs (til) liés à la sélection de cd39/cd103
WO2024098024A1 (fr)	2022-11-04	2024-05-10	Iovance Biotherapeutics, Inc.	Expansion de lymphocytes infiltrant les tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
TW202435917A (zh)	2022-11-17	2024-09-16	美商西雅圖遺傳學公司	Ceacam5抗體-藥物接合物及其使用方法
EP4623072A2 (fr)	2022-11-21	2025-10-01	Iovance Biotherapeutics, Inc.	Procédés bidimensionnels pour l'expansion de lymphocytes infiltrant les tumeurs et thérapies associées
WO2024112711A2 (fr)	2022-11-21	2024-05-30	Iovance Biotherapeutics, Inc.	Procédés d'évaluation de la puissance de prolifération de lymphocytes t génétiquement modifiés
WO2024129756A1 (fr)	2022-12-13	2024-06-20	Seagen Inc.	Conjugués anticorps-médicament modifiés par la cystéine spécifiques d'un site
WO2024133845A1 (fr)	2022-12-22	2024-06-27	Tubulis Gmbh	Conjugués comprenant une fraction phosphore (v) et un médicament
WO2024151885A1 (fr)	2023-01-13	2024-07-18	Iovance Biotherapeutics, Inc.	Utilisation de til en tant que thérapie de maintenance pour des patients atteints de nsclc qui ont atteint une pr/cr après une thérapie antérieure
WO2024171078A1 (fr)	2023-02-14	2024-08-22	H. Lundbeck A/S	Traitement de la douleur induite par les opioïdes
JP2026506893A (ja)	2023-02-23	2026-02-27	イムチェックセラピューティクスエスエーエス	Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
EP4673225A2 (fr)	2023-02-27	2026-01-07	Compugen Ltd.	Polythérapie triple avec des anticorps anti-pvrig, des anticorps anti-tigit et du pembrolizumab
CN120936679A (zh)	2023-03-17	2025-11-11	贝克曼库尔特有限公司	苯并噻吩并吡咯花菁染料
CN121194989A (zh)	2023-03-30	2025-12-23	272生物有限公司	GnRH结合多肽及其用途
WO2024206738A1 (fr)	2023-03-31	2024-10-03	Immunai Inc.	Anticorps anti-trem2 humanisés
EP4442276A1 (fr)	2023-04-07	2024-10-09	Institut Pasteur	Anticorps combinés contre les sarcovirus et leurs utilisations
WO2024220889A1 (fr)	2023-04-20	2024-10-24	Seagen Inc.	Composés agonistes de sting et leurs conjugués
TW202506731A (zh)	2023-04-27	2025-02-16	法商感應檢查療法公司	治療多重抗藥性細菌感染之方法
WO2024236156A1 (fr)	2023-05-17	2024-11-21	Institut National de la Santé et de la Recherche Médicale	Anticorps anti-cathepsine d
EP4725967A1 (fr)	2023-06-12	2026-04-15	Nanjing Probio Biotech Co., Ltd.	Anticorps se liant au ccr8 humain et son utilisation
EP4477236A1 (fr)	2023-06-14	2024-12-18	Inatherys	Polythérapie pour le traitement d'une tumeur à l'aide d'un adc comprenant des anticorps anti-cd71 et des mimétiques bh3
WO2024261239A1 (fr)	2023-06-23	2024-12-26	Imcheck Therapeutics	Anticorps bispécifiques ciblant btn3a et l'axe inhibiteur de pd-1/pd-l1
CR20250530A (es)	2023-06-23	2026-01-12	H Lundbeck As	Tratamiento combinado
TW202515608A (zh)	2023-06-26	2025-04-16	以色列商坎布根有限公司	Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025012417A1 (fr)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anticorps à fragments longs anti-neurotensine et anti-neuromédine n et leurs utilisations
AU2024296516A1 (en)	2023-07-13	2026-01-22	Iovance Biotherapeutics, Inc.	Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
AU2024292473A1 (en)	2023-07-19	2026-01-29	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025024265A1 (fr)	2023-07-21	2025-01-30	Bristol-Myers Squibb Company	Procédés d'évaluation de la citrullination et de l'activité de modulateurs de pad4
WO2025046090A1 (fr)	2023-09-01	2025-03-06	Tubulis Gmbh	Procédés de préparation de composés phosphonamidate
WO2025064842A1 (fr)	2023-09-21	2025-03-27	Beckman Coulter, Inc.	Colorants pontés par dihydrophénanthrène (dhp) destinés à être utilisés en cytométrie en flux
WO2025085489A1 (fr)	2023-10-17	2025-04-24	Bristol-Myers Squibb Company	Composés de dégradation de gspt1, anticorps anti-cd33 et conjugués anticorps-médicament, et leurs utilisations
WO2025090774A1 (fr)	2023-10-24	2025-05-01	Seagen Inc.	Composés chimiothérapeutiques et procédés d'utilisation
WO2025101484A1 (fr)	2023-11-06	2025-05-15	Iovance Biotherapeutics, Inc.	Traitement de cancers endométriaux avec des thérapies lymphocytaires infiltrant les tumeurs
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025149947A1 (fr)	2024-01-12	2025-07-17	Seagen Inc.	Conjugués anticorps-médicament
WO2025155877A2 (fr)	2024-01-18	2025-07-24	The Regents Of The University Of California	Anticorps se liant à la pad4 humaine et leurs utilisations
WO2025153707A1 (fr)	2024-01-19	2025-07-24	Spikimm	Anticorps monoclonaux neutralisants à large spectre dirigés contre le sars-cov-2 et leurs utilisations
WO2025171182A1 (fr)	2024-02-08	2025-08-14	Iovance Biotherapeutics, Inc.	Traitement de patients atteints d'un cancer au moyen de thérapies par lymphocytes infiltrant les tumeurs en combinaison avec un vaccin contre le cancer
WO2025174974A1 (fr)	2024-02-14	2025-08-21	Bristol-Myers Squibb Company	Anticorps anti-cd33 et leurs utilisations
EP4658320A1 (fr)	2024-02-27	2025-12-10	Bristol-Myers Squibb Company	Conjugués anticorps anti-ceacam5-médicament
TW202600608A (zh)	2024-02-27	2026-01-01	美商必治妥美雅史谷比公司	抗ｃｅａｃａｍ５抗體及其用途
WO2025191147A1 (fr)	2024-03-14	2025-09-18	Synabs	Anticorps anti-ccr8 et leurs utilisations
WO2025199352A2 (fr)	2024-03-20	2025-09-25	Juno Therapeutics, Inc.	Anticorps spécifiques du membre 2 de la famille des transporteurs de solutés 34 (slc34a2)
WO2025224297A1 (fr)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Anticorps ayant une spécificité vis-à-vis de tgfbi et leurs utilisations
WO2025242732A1 (fr)	2024-05-21	2025-11-27	Institut National de la Santé et de la Recherche Médicale	Anticorps pan dirigés contre la protéine de spicule du sars-cov-2 et leurs utilisations à des fins thérapeutiques
WO2025255405A1 (fr)	2024-06-06	2025-12-11	Bristol-Myers Squibb Company	Anticorps anti-fap et leurs utilisations
WO2025255349A1 (fr)	2024-06-06	2025-12-11	Bristol-Myers Squibb Company	Anticorps anti-cd40/anti-fap multispécifiques et leurs utilisations
WO2025257181A1 (fr)	2024-06-11	2025-12-18	Institut National de la Santé et de la Recherche Médicale	Anticorps ciblant la protéine-43 de liaison à l'adn à réponse trans-active (tdp-43)
US20260001942A1 (en)	2024-06-21	2026-01-01	H. Lundbeck A/S	Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto
WO2026006784A1 (fr)	2024-06-28	2026-01-02	Iovance Biotherapeutics, Inc.	Procédés de fabrication de lymphocytes de sang périphérique réactifs aux tumeurs (trpbl)
WO2026035866A1 (fr)	2024-08-07	2026-02-12	Iovance Biotherapeutics, Inc.	Traitement de patients atteints d'un cancer par des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un inhibiteur de lag-3 et un inhibiteur de pd-1
WO2026043823A2 (fr)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Anticorps comprenant des résidus d'acides aminés non naturels spécifiques à un site, leurs procédés de préparation et leurs utilisations
WO2026050217A2 (fr)	2024-08-27	2026-03-05	Iovance Biotherapeutics, Inc.	Cellules présentatrices d'antigènes artificielles modifiées et nanoparticules lipidiques pour l'expansion de lymphocytes infiltrant les tumeurs
WO2026052839A1 (fr)	2024-09-06	2026-03-12	Hone Bio Limited	Protéines de fusion de ciblage
WO2026068504A2 (fr)	2024-09-24	2026-04-02	The University Of Bristol	Nouveaux conjugués protéiques
WO2026072794A2 (fr)	2024-09-26	2026-04-02	Iovance Biotherapeutics, Inc.	Procédés d'expansion pour produit de til enrichi en lymphocytes t réactifs aux néoantigène (nart)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1609546A (en) *	1925-11-19	1926-12-07	Petroleum Rectifying Co	Process of separating water from emulsions
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en) *	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
JPS57192435A (en) *	1981-05-20	1982-11-26	Toyobo Co Ltd	Modified polypeptide
US6936694B1 (en) *	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
EP0098110B1 (fr) *	1982-06-24	1989-10-18	NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD	Composition à action prolongée
EP0154316B1 (fr) *	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Lymphokine chimiquement modifiée et son procédé de préparation
JPS61227526A (ja) *	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
JPS6142558A (ja) *	1984-08-06	1986-03-01	Matsushita Electric Works Ltd	アミノ樹脂成形材料
EP0215126B1 (fr) *	1985-02-08	1991-07-31	Chugai Seiyaku Kabushiki Kaisha	Facteur de stimulation de colonies de granulocytes humains
JPS62129298A (ja) *	1985-12-02	1987-06-11	Chugai Pharmaceut Co Ltd	新規ポリペプチド
US5532341A (en) *	1985-03-28	1996-07-02	Sloan-Kettering Institute For Cancer Research	Human pluripotent hematopoietic colony stimulating factor
DE3676670D1 (de) *	1985-06-26	1991-02-07	Cetus Corp	Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en) *	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
ES8800982A1 (es) *	1985-07-05	1987-12-01	Takeda Chemical Industries Ltd	Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
JPS6236488A (ja) *	1985-08-11	1987-02-17	Semiconductor Energy Lab Co Ltd	強誘電性液晶及びその作製方法
JPS63500636A (ja) *	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) *	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
JPH0657152B2 (ja) *	1985-09-17	1994-08-03	中外製薬株式会社	Ｃｓｆ遺伝子類
JP2514950B2 (ja) *	1986-03-10	1996-07-10	エフ・ホフマン―ラロシユアーゲー	化学修飾蛋白質，その製造法および中間体
CA1283046C (fr) *	1986-05-29	1991-04-16	Nandini Katre	Facteur de necrose des tumeurs
JPS63126900A (ja) *	1986-06-26	1988-05-30	Takeda Chem Ind Ltd	化学修飾蛋白質
US4791192A (en) *	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
JPS6360938A (ja) *	1986-09-02	1988-03-17	Meiji Milk Prod Co Ltd	修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
US4894226A (en) *	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5214132A (en) *	1986-12-23	1993-05-25	Kyowa Hakko Kogyo Co., Ltd.	Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) *	1986-12-23	1994-11-08	Kyowa Hakko Kogyo Co., Ltd.	Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) *	1986-12-23	1993-03-16	Kyowa Hakko Kogyo Co. Ltd.	Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
JPH086063B2 (ja) *	1987-07-22	1996-01-24	日本ペイント株式会社	親水性表面処理剤及び処理方法
US4904584A (en) *	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
US4847325A (en) *	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
JPH0796558B2 (ja) *	1988-03-31	1995-10-18	協和醗酵工業株式会社	修飾ポリペプチド
CA1340810C (fr) *	1988-03-31	1999-11-02	Motoo Yamasaki	Derives de polypeptides actifs comme facteurs stimulant les colonies de granulocytes chez l'homme
US5218092A (en) *	1988-09-29	1993-06-08	Kyowa Hakko Kogyo Co., Ltd.	Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) *	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6166183A (en) *	1992-11-30	2000-12-26	Kirin-Amgen, Inc.	Chemically-modified G-CSF
EP0401384B1 (fr) *	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
WO1990009798A1 (fr) *	1989-02-24	1990-09-07	Immunotherapeutics, Inc.	Cytokines immobilisees
US5166322A (en) *	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
US5372808A (en) *	1990-10-17	1994-12-13	Amgen Inc.	Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) *	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) *	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
US5382657A (en) *	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
US5581476A (en) *	1993-01-28	1996-12-03	Amgen Inc.	Computer-based methods and articles of manufacture for preparing G-CSF analogs
JP2966686B2 (ja) *	1993-04-20	1999-10-25	三洋電機株式会社	半導体レーザの製造方法
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5672662A (en) *	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications

1989
- 1989-12-22 EP EP90900360A patent/EP0401384B1/fr not_active Expired - Lifetime
- 1989-12-22 DE DE68925966T patent/DE68925966T2/de not_active Expired - Lifetime
- 1989-12-22 WO PCT/JP1989/001292 patent/WO1990006952A1/fr not_active Ceased
- 1989-12-22 AT AT90900360T patent/ATE135370T1/de not_active IP Right Cessation
- 1989-12-22 CA CA002006596A patent/CA2006596C/fr not_active Expired - Lifetime
- 1989-12-22 JP JP50114490A patent/JP2989002B2/ja not_active Expired - Fee Related
1992
- 1992-11-30 US US07/983,620 patent/US5824778A/en not_active Expired - Lifetime
2007
- 2007-03-12 US US11/716,866 patent/US20070219357A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE68925966D1 (de)	1996-04-18
CA2006596C (fr)	2000-09-05
EP0401384B1 (fr)	1996-03-13
ATE135370T1 (de)	1996-03-15
EP0401384A1 (fr)	1990-12-12
JP2989002B2 (ja)	1999-12-13
DE68925966T2 (de)	1996-08-29
US5824778A (en)	1998-10-20
US20070219357A1 (en)	2007-09-20
WO1990006952A1 (fr)	1990-06-28
EP0401384A4 (en)	1991-09-25

Legal Events

Date	Code	Title	Description
1996-12-18	EEER	Examination request
2009-12-22	MKEX	Expiry

Publication	Publication Date	Title
CA2006596A1 (fr)	1990-06-22	G-csf modifie chimiquement
HK102192A (en)	1992-12-24	Human tumor necrosis factor and dna therefor
AU629649B2 (en)	1992-10-08	Novel procoagulant proteins
IL94361A0 (en)	1991-03-10	Polypeptides,recombinant dna molecules and method of producing a human hemoglobin like protein
CA2094027A1 (fr)	1992-04-19	Peptides osteogenes
CA2089094A1 (fr)	1992-02-08	Expression de polypeptides recombinants et methode de purification amelioree
GR3021198T3 (en)	1996-12-31	Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)
HK49285A (en)	1985-07-05	Interferons and process for their preparation
ZA908166B (en)	1991-08-28	Erythropoietin isoforms
AU558812B2 (en)	1987-02-12	Dentifrice containing partially hydrolyzed protein fraction rich in positively charged amino acids
AU1094892A (en)	1992-08-27	Improved activation of recombinant proteins
AU2682388A (en)	1989-05-25	Diagnostic system
ZA894721B (en)	1990-03-28	Leader sequence inducing a post-translational modification of polypeptides in bacteria,and gene therefor
NO177270C (no)	1995-08-16	Fremg. for fremstilling av terapeutisk aktive, humane granulocytt-makrofag-"kolonistimulerende"-faktorproteiner (GM-CSF), bakteriell ekspresjonvektor som er i stand til å uttrykke GM-CSF samt bakteriecelle inneholdende vektoren
AU2308992A (en)	1993-02-11	Cysteine depleted il-6 muteins
EP0810285A3 (fr)	1998-07-08	Mutants de l'interleukine-3 humaine
GB8616219D0 (en)	1986-08-13	Monoclonal antibodies
CA2163805A1 (fr)	1996-05-29	Nouveau facteur d'activation des leucocytes
AU637589B2 (en)	1993-06-03	Ancrod proteins, their production and use
EP0317279A3 (fr)	1989-11-02	Peptides pour l'usage dans la purification du facteur-VIII
WO1992001794A3 (fr)	1992-03-05	Proteines semblables a l'ancrod, leur fabrication et utilisation
WO1990000179A3 (fr)	1990-03-08	Nouvelles proteins, adn les codant et leur usage
DE3876240D1 (fr)	1993-01-07
CA2247998A1 (fr)	1997-09-04	Fragments de recepteur du complement de type 1 et leurs utilisations
AU3327789A (en)	1989-10-26	Expression of the hiv 24 kda 24 gag protein in methylotrophic yeast